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INTRODUCTION 
FUNCTIONAL VISION1 
The term functional vision explains the effect of  vision on quality of 
life. To recognise face and its expression,reading newspapers,driving a car or 
bike at night,performing highly skillful  tasks,all  are related to functional 
vision to ophthalmic patients. 
Acuity, which is typically used to evaluate vision is not as strongly 
related to many everyday activities as was previously believed. The 
American Academy of Ophthalmology1 states that “We know intuitively that 
given the appriopiate set of circumstances,each of us with 20/20 vision will 
function as visually handicapped individuals.Thus when a person is driving in 
to sun at dusk or dawn,change in contrast sensitivity and effect of glare alter 
detail discrimination.” 
 Studies showed  that contrast sensitivity is a strong indicator of visual 
function2,3.Contrast sensitivity testing determines the association between 
optical clarity and the minimum retinal threshold for particular pattern of the 
object3,4.Therefore contrast sensitivity strongly denotes functional vision as a 
whole .Vision is most important  of all senses.It is that most  of the 
information from the external  world is appreciated through the visual 
system. 
 
 
 
 
Loss or reduced vision has a strong value on the visual ability and  quality of 
life.Yet,for all vision is importance to each of us,the most common clinical 
measurement of it is relatively crude and narrow.The process of vision 
includes many functions such as 
Central resolution(Visual Acuity) 
Minimal light Sensitivity 
Contrast sensitivity 
Detection of motion 
Colour perception 
Colour contrast 
Peripheral vision 
In the normal clinical setting,we measure only one of the functions-
Central resolution of high contrast(Visual acuity).That ,this one simple test 
does a pretty good job for detecting most visual dysfunction is truly 
amazing,despite the fact that visual acuity is to all of visual perception,as the 
elephant trunk is to the whole elephant. 
 
 
 
 
 
 
TERMINOLOGY FOR VISUAL FUNCTIONS5,6: 
The Minium Visible: 
Minimum visible acuity is an example of brightness discrimination( to 
detect small changes in the brightness of two light sources) although it is 
often misclassified as spatial sense.If the target is a luminous object on a 
perfectly dark background,this test measures the brightness sensitivity of the 
eye.The minimum visible is determined not by the visual angle subtended by 
an object but rather by its brightness relative to the background illumination. 
The Minimum Perceptive: 
This acuity is concerned with detection of fine objects such as dots or 
lines against a homogenous background.The object need not be identified or 
named,merely detected.The minimum perceptive is a measure of brightness 
discrimination.The threshold associated with minimum perceptible acuity is 
called the detection threshold. 
The Minimum Seperable: 
The smallest visual angle at which two separate objects can be 
discriminated is called minimum seperable.It depends on object contrast and 
packing density of photoreceptors in the fovea,Two part discrimination 
,Landolt C resolution ,the E game and grating acuity are clinical examples of 
 
 
 
 
minimum seperable tasks.The threshold associated with minimum seperable 
acuity is known as resolution threshold. 
Vernier Acuity(Hyper acuity) 
The human eye has special ability for spatial localisation .It can detect 
two parallel lines and straight line in a particular plane. 
Minimum Legible: 
This acuity is the measure of the spatial sense that is most familiar to 
clinicians.It tests the patients ability to recognise progressively smaller letters 
or forms,frequently referred to as optotypes.The angle that the small 
recognizable letter or symbol subtends on the retina is a measure of visual 
acuity.The threshold associated with minimum legible acuity is called the 
recognition threshold. 
 
 
 
 
 
 
 
 
 
 
QUALITY OF LIFE 
To explain and identify the patient satisfaction a new concept was 
introduced i.e., the concept of quality of life.Thus quality of life is a unique 
parameter8 which has been assessed to find out the acceptance and 
effectiveness of our services among the population by recording patients 
judgement(eg.Sickness impact profile)9 or provider based assessment i.e., 
clinician’s assessment of patient’s functional state(Functional Independence 
Measure)10 or proxy based assessment,ascertains the judgement of the family 
or of other lay people(Functional activities Questionnaire) 11 
           The Quality Of Life is a strictly a personalised issue.Thus there is a 
strong association between the health related quality of life measurement and  
patient defined issues7 
19WHO defined “Quality of Life” as “a composite measure of 
physical,mental and social wellbeing as perceived by each individual or by 
group of individuals –that is to say ,happiness,satisfaction and gratification as 
it is experienced in such life concerns are health,marriage,family 
work,financial situation,educational oppurtunities,self esteem,creativity,and 
trust in others” 
 
 
 
 
Nowadays,People needs a good quality of life.So,Health care providers 
are concentrating on increasing quality of life  by providing hospitality and  
adequate treatment to the disease or medical or surgical conditions. 
In Ophthalmology, the Quality of life and visual functions has been 
assessed with visual function assessment questionnaires for many diseases 
like Cataract,Age related macular degeneration,Glaucoma,Low vision 
patients14,15,16,17 etc.,.But still lot of work is yet to be done .And hence it was 
decided to analyse “the quality of life in Uveitic Patients” and to verify the 
effect of treatment in the same population and to correlate with the contrast 
sensitivity in day and night vision with and without glare. 
 
 
 
 
 
 
 
 
 
 
 
 
 
UVEITIS 
      Uveitis,an inflammatory disease of the uveal tract(iris, ciliarybody, 
choroid) of the eye. Uveitis are vision threatening condition which are 
relatively under appreciated by the general practioniares and comprehensive 
ophthalmologists.Few people realise,Uveitis are responsible for leading cause 
of blindness in developed countries and one of the cause of preventable 
blindness in developing countries like India.The maximum incidence occurs 
in 25-50 years age group(working age),the visual impairment in this age 
group causes economic consequences. 
 
Uveitis is classified on the basis of  
1.Anatomy 
2.Clinical features 
3.Aetiology 
 
 
 
 
 
 
 
 
Anatomical Classification21: 
A.Anterior Uveitis 
      Defined as “ inflammation of iris and anterior part of ciliary body” 
       1.Iritis 
       2.Iridocyclitis 
       3.Anterior cyclitis 
Based on the type of inflammation ,”Anterior Uveitis can be further classified 
as” 
       1.Non-Granulamatous Uveitis 
       2.Granulamatous Uveitis 
B.Intermediate Uveitis 
           Defined as “  inflammation of posterior part of ciliary body (Pars 
Plana),the extreme periphery of the retina and the underlying Choroid”. 
C.Posterior Uveitis 
Defined as “ inflammation of retina posterior to the vitreous base and 
choroid” 
 
 
 
 
 
It is classified morphologically as 21 
 1.Focal 
2.Multifocal 
3.Geographical 
D.Panuveitis 
                   “ It invoves inflammation of the entire Uveal tract” 
Clinical Classification21: 
A.Acute Uveitis: 
Termed as”  It is of sudden onset and persists for 3 months”.If it recurs 
following  inital attack,it is called Recurrent acute 
B.Chronic Uveitis: 
                     Termed as “It lasts longer than 3 months. It is of insidious 
onset.It may be asymptomatic, although acute or subacute exacerbations may 
occur.” 
 
 
 
 
 
 
 
Aetiological Classification21: 
In this “ uveitis is caused by external injury to uvea or invasion by 
microorganisms or from other agents with in the patients called Exogenous 
uveitis.”Types are 
1.Infection with bacteria,Fungi,Viruses 
2.Infestation with protozoa,Nematodes 
3.Associated with a systemic disease 
4.Idiopathic Specific uveitis 
5.Idiopathic Non-specific Uveitis 
“SUN Working Group” :Description of Uveitis21,23 
Onset may be sudden or insidious 
Duration:limited-if it is of less than 3 months duration 
                 Persistent- if it is of more than three months duration 
Course:In Acute condition there will be a sudden onset and limited duration 
              In Recurrent condition there will be a recurrent episodes with an 
interval of inactivity in absence of treatment for three months. 
            In Chronic condition there will be a Persistent uveitis and relapse in 
less than 3months after discontinuation of  treatment  
 
 
 
 
            In Remission there will be an inactive disease for atleast three months 
after discontinuation of treatment 
 
“International Uveitis Study group” recommendation for “Anatomical 
classification of Uveitis”24 
Anterior Uveitis Intermeiate 
Uveitis(formerly 
known as Pars 
Planitis) 
Posterior Uveitis Pan Uveitis 
Iritis 
Iridocyclitis 
Anterior cyclitis 
Posterior cyclitis 
Hyalitis 
Basal 
Retinochoroiditis 
Focal 
Multifocal 
Diffuse 
Choroiditis 
Chorioretinitis 
Retinochoroiditis 
Focal 
Multifocal 
Diffuse 
Choroiditis 
Chorioretinitis 
Retinochoroiditis 
 
 
 
 
 
 
 
“SUN Working group” :Activity of Uveitis terminology21,23 
1.Inactive-Grade 0 cells in Anterior chamber 
2.Worsening Activity-if it is of two step incremental in inflammation 
3.Improving Activity-if it is of two  step decremental in inflammation 
4.Remission- disease that is inactive for morethan three months once all 
treatment is discontinued. 
Clinical workup: 
It starts with proper history taking which includes complete ocular and 
systemic history 
Symptoms of uveitis include 
Rednes,Pain,Photophobia,Watering,Visual disturbances,Floaters 
Signs of uveitis include 
Circumcorneal congestion, Keratic precipitates, inflammatory cells, flare, 
hypopyon, iris nodules, synechiae-Anterior and posterior, band keratopathy, 
inflammatory cells and bands in vitreous, snow banking, retinal edema, 
cystoid macular edema, epiretinal membranes, infiltrates, neovascularisations 
etc., 
 
 
 
 
 
SUN Classification for grading of Anterior Chamber cells21,23 
Cells in field Grade 
<1 0 
1-5 0.5+ 
6-15 1+ 
16-25 2+ 
26-50 3+ 
>50 4+ 
SUN classification for grading of Aqueous Flare21,23 
Description Grade 
Nil 0 
Just detectable 1+ 
Moderate 2+ 
Marked 3+ 
Intense 4+ 
 
 
 
 
 
 
 
 
Laboratory Investigations25,26,27,28 
It includes General and Specific investigations. 
1.General Investigations: 
Complete blood count 
Chest X-ray 
Erythrocyte Sedimentation Rate 
FTA-ABS,TPHA,VDRL for Syphilis 
Mantoux test for Tuberculosis 
Other investigations to rule out systemic illness like diabetes 
2.Specific Investigations: 
ACE(Angiotensin converting Enzyme ) for Sarcoidosis 
ANA (Anti Nuclear Antibody)-Autoimmune disorders 
ANCA(Anti Neutrophill Cytoplasmic Antibody)-Wegner’s Granulomatosis 
Choroidal biopsy 
Conjunctival biopsy-Sarcoidosis 
CT scan of Orbits and B-Scan –Posterior scleritis 
CT Scan chest-Sarcoidosis 
 
 
 
 
Enucleated eyeball for Histopathology-Sympathetic Ophthalmia 
ELISA-leptospirosis,Toxoplasmosis,Toxocariasis 
FFA and ICG 
Western blot for HIV 
MAT(Micro Agglutination Test)-Leptospirosis 
MRI Brain-Lymphoma and Neurosarcoidosis 
OCT 
PCR  
Rheumatoid factor 
UBM for angle structures study 
Vitreous biopsy 
Laser flare meter 
 
 
 
 
 
 
 
 
 
Principles of treatment27,30,31,32 
The main aim of the treatment is to prevent the complications,to 
relieve patient’s discomfort and to treat the underlying cause. 
The drugs commonly used for the treatment of uveitis include 
topical/systemic/periocular steroids in addition with mydriatrics and 
cycloplegics 
Prednisolone Acetate 1% ophthalmic suspension is the most commonly 
used topical steroid for uveitis.The drug should be dosed according to disease 
activity. 
Triamcinolne Acetonide  is the drug mostly preferred for posterior sub-
tenon injection.It may also used for intermediate, posterior and panuveitis. 
Systemic steroids are the main stay of drug in the treatment of 
uveitis.Usually started as 1mg/kg/day for a month or till the disease is under 
control. 
Immunosuppressives like Alkylating agents,T-cell inhibitors,anti-metabolites 
are used when there is no response to steroids or when side effects of steroids 
are not tolerated.Methotrexate and Cyclosporine are most commonly used as 
immunosuppressive agents. 
 
 
 
 
Newer biological are the class of drugs used to treat autoimmune 
disease.Etarnacept,Anakinra,Adalimumab,Infliximab are the examples of 
newer biological used in the treatment of autoimmune disease. 
All systemic therapy should be given under guidance with Physician and 
Rheumatolgist.Side effects of the drug should be keep in mind while 
prescribing systemic drugs.  
Apart from medical treatment,surgical treatment may also be required in 
special situations. 
The indications include Phaco-antigenic uveitis,Complicated 
cataract,glaucoma filtering surgery for uncontrolled elevated Intraocular 
pressure inspite of maximum tolerable medical therapy,vitrectomy,ILM 
peeling,Retinal detachment surgeries etc., 
In uveitis,it is mandatory to wait for atleast 3 months after the last episode 
of an active disease to undergo an elective surgery for visual 
rehabilitation.Complications of cataract surgery in uveitis include Posterior 
capsular rent,Cystoid Macular Edema,Secondary Glaucoma,persistent 
inflammation and early posterior capsular opacification. 
 
 
 
 
 
 
 
PHYSIOLGY OF VISION33,34 
It  is a multiple phenomenon.The mechanisms are less understood. The 
mechanisms concerned with vision are:  
· Initiation of vision (Transduction),  
· Transmission of visual sensation, and  
· Visual perceptions  
 
Initiation and transmission of visual sensations  
The photoreceptors like rods and cones are the receiving nerve endings 
for a visual stimuli. Stimuli for visual sensations may be divided, in a purely 
physical sense, into two types inadequate and adequate. 
Inadequate stimuli produce glowing sensations called phosphenes. 
Mechanical stimulation by pressure. on the sclera is an example of 
inadequate stimulus which produces pressure phosphene (which appears as a 
patch with contrasting border). Other examples of inadequate stimuli are 
rapid eye movements in dark (producing movement phosphene), passage of 
weak electric current through retina (producing electrical Phosphene) and 
passage of X-rays or other ionizing radiations through the retina (producing 
radiation phosphenes),  
 
 
 
 
Adequate stimuli to vision are formed by visible portion of the 
electromagnetic radiation spectrum, i.e.,‘the light'. It is the spectrum of 
wavelength lies between 400 nm to 750nm.It is the white light lies between 
violet end and Red end of visible spectrum.It is the concentric waveforms 
that produce light ray,these parallel rays of light is needed to produce beam 
of light. 
Light falling upon the retina is absorbed by the photosensitive 
pigments present in the rods and cones, and initiates photochemical change in 
the retina.These changes tigger a sequence of events (electrical changes) that 
initiate the visual sensations. The retinal receptors are not just transducers of 
light into chemical and electrical signals. they are active processors of 
information. Thus the electrical potential changes produced and actively 
processed in the retina are transmitted through the   ganglion cells and along 
the fibers of the optic nerve and other parts of the visual pathway to the visual 
cortex. 
 
 
 
 
 
 
 
 
 
 
Visual perceptions 
 Visual perceptions are the functional elements of the vision –it is 
perceived when the light rays stimulate the retina. These are of four types 
named as “ the light sense, the form sense, the contrast sense and the colour 
sense.” 
The light sense 
 The Light sense refers to the appreciations (awareness) of light and its 
intensity. The brightness required to induce a light sensation is called light 
minimum.It is measured after 20-30 minutes after dark adaptation. Dark 
adaptations is the ability of the eye to adapt itself to decreasing illumination. 
The rods are much more sensitive to low illumination.The rods are the most 
sensing receptor for low illumination than cones. This form the basis of the 
Duplicity. Vision theory states that “rods are used more in dim light (scotopic 
vision) and cones in bright light (Photopic vision)”.. 
The form sense 
It is the ability of eye to differentiate the size and shapes of the 
objects.Cone is the sensitive receptor to perceive this difference.Snellen’s 
chart to measure visual acuity is an example for measuring form sense. 
 
 
 
 
 
 
Sense of contrast 
 It is the ability of the eye to differentiate slight change in luminance 
between th objectsin which there is no well defined border between the 
objects. 
 
The colour sense 
 It is the ability of the eye to differentiate colours of different 
wavelength  which are excited by light.Cones perform this function by 
different types of pigments which absorb red, green and blue wavelengths or 
light (primary colours).  
Other phenomena associated with physiology of vision are included in the 
following sections: 
• Critical flicker fusion frequencies 
• Entoptic and allied phenomena 
There are three system pathways associated with colur sense.These three 
systems process the information as parallel systems. Each of these systems 
processes the information from all the three systems is then integrated into a 
single visual perception. 
 
 
 
 
 
VISUAL ACUITY33,34 
Visual acuity is a measure of form sense, so it refers to the spatial limit 
of visual discrimination. In terms of visual angle, the visual acuity is defined 
as “ the reciprocal of the minimum resolvable visual angle measured in 
minutes of arc of a standard test pattern”. It is necessary to understand about 
visual angle. 
Visual Angle 
It is the angle measured at the nodal point of the eye in the object space 
of visual field.  
Components of visual acuity  
Visual acuity consists of the following components: 
· Minimium visible 
· Resolution 
· Recognition 
· Minimum discriminable. 
Minimum Visible 
The ability of eye to identify object in visual field is called visibility or 
detection. This kind of task is referred to as the minimum visible or minimum 
detectable function. The limit of visibility reflects the absolute threshold of 
 
 
 
 
vision. The minimum visible spatial threshold level will depend upon the 
specification of stimulus such as size, shape, illumination. A few 
observations made about the minimal visible threshold are as follows: 
· A black dot against a white background can be detected, if its diameter 
is of the order of 30 seconds of arc or more. 
· A black square can be discriminated against a light background when 
the length of a diagonal is 30 seconds. 
· An extended line (e.g. visualization of a thin telegraph wire against a 
uniform sky) with a thickness of as little as one-half second of arc may 
be discriminable. The ability to discriminate such a fine line when its 
image is of sufficient extent implies dependence upon some kind of 
process that involves the convergence of subthreshold signals from a 
number of individual retinal elements along the extent of retinal image 
at a common point. The addition of these subthreshold signals yields a  
discriminable suprathreshold level of activity. 
· Detection of an illuminated object against a dark background solely 
depends upon its intensity and not on its size. 
Resolution  
The ability of eye to differentiate two spatially separated objects is called 
minimum resolvable.The measurement of threshold of differentiation is 
visual acuity. 
 
 
 
 
· If the minimum separation between two light bars is considered, the 
threshold value becomes increasingly smaller as the width of the bars 
increases, reaching a limiting condition of approximately one-half 
second of arc when the light bars have become so broad that the overall 
presentation is indiscriminable from a dark line against a large 
homogenous light background. 
· The minimum separation, which can be discriminated between two 
dark bars, will become infinite, as the bars become wider and the 
stimulus is seen as light line against a dark background. 
· The tests to measure visual acuity is form sense.Resolution is the 
ability to identify the spatial characteristics of a test figure. The test 
targets in these tests may either consider of letters (Snellen’s chart) or 
broken circles (Landolt’s ring). More complex targets include gratings 
and checkerboard patterns. 
Recognition 
Ability of the individual to identify the pattern of the objects or 
images.Example of recognition is the identification of person. 
Minimum discriminable or hyperacuity 
It is the ability of person to identify objects at lower threshold. The 
example is Vernier acuity.e.,the ability of person to identify two parallel or 
straight lines in a particular plane.The threshold values of vernier acuity  are 
 
 
 
 
in the range of only few seconds (2-10) of arc. Hyperacuity should not be 
confused with the threshold for the minimum visible, where merely the 
presence or absence of a target is being judged. The mechanism subserving 
hyperacuity is not clearly known, but so much is clear; no contradiction is 
involved with the optical and recptor mosaic factors that limit ordinary visual 
acuity. 
FACTOR AFFECTING VISUAL ACUITY33,34 
As discussed earlier, resolution part of the spatial discrimination is 
considered synonymous with the ordinary visual acuity. And we know that 
where an observer exhibits the so-called normal visual acuity, all the 
elements (optical, anatomical and physiological) concerned with the vision 
are near their peak performance. In general, the factors that influence the 
spatial resolution can be classified into physical and physiological. 
· Physical factors include those which influence the light characteristics 
of the distribution and hence influence the nature of retinal image. 
· Physiological factors are those which influence the processing of the 
stimulus and are thus mainly observer related. However, there is some 
overlap between physical and physiological groups. For example, the 
lens is a physical factor but the related accommodation process is 
physiological. Similarly, the size of pupil that controls the amount of 
light entering the eye is a physical factor but the reflexes controlling its 
 
 
 
 
size are physiological process. 
Therefore, these factors have been classified into stimulus-related and the 
observer-related factors. Further, the list of such factors is exhaustive, but 
only the important ones are mentioned here briefly. 
Stimulus-related factors 
1. Luminance of test object 
2. Geometrical configuration of the stimulus 
3. Contrast of the stimulus from the surround 
4. Influence of wavelength of stimulus light 
5. Exposure duration of stimulus 
6. Interaction effects of the two targets 
 
Observer-related factors 
1. Retinal locus of stimulation 
2. Pupil size 
3. Accommodation 
4. Effect of eye movements 
5. Meridional variation in acuity 
6. Optical elements of the eye 
7. Developmental aspects 
 
 
 
 
MEASURMENT OF VISUAL ACUITY33,34 
Visual acuity consists of 
1.Minimum visible 
2.Minimum seperable 
3.Minimum resolvable 
In clinical practice, the measurement of visual acuity is considered 
synonymous with the measurement of minimum resolvable. The minimum 
resolvable falls with in the threshold of 30 seconds and 1 minute of arc. 
Therefore, all the clinical tests employed to measure the visual acuity are 
designed taking into consideration the threshold of the one minimum 
resolvable. Based on this basic principle, many visual acuity charts have been 
developed.  
Examination with eye charts is quite satisfactory, but this is obviously 
incomplete. It emphasizes on foveal vision, usually at one level of 
illumination, and adaptation at one distance. In order to be complete, it must 
be supplemented by other tests for near vision at lower luminances,contrast 
sensitivity and  as well as with some test of peripheral function. 
It is important to realize that although assessing visual acuity in 
children may be difficult and often demands painstaking patience; its 
interpretation should be done in the light of the overall clinical picture. As no 
 
 
 
 
single test is dependable, one must try and use a battery of tests which may 
be repeated on subsequent follow-ups. 
The various visual acuity tests available can be grouped as follow: 
I. Detection acuity test.  
These assess the ability to detect the smallest stimulus without 
recognizing correctly. Common detection acuity tests are: 
1. Dot visual acuity test 
2. Catford drum test 
3. Boek candy beads test 
4. STYCAR graded Ball’s test 
5. Schwarting metronome test 
II. Recognition acuity tests.  
       These are designed to assess the ability to recognize the stimulus or to 
distinguish it from other competing stimuli. These include: 
(A) Direction identification tests 
1. Snellen’s E-Chart test 
2. Landolt’s C-chat test 
3. Sjogren’s hand test 
4. Arrows test 
 
 
 
 
 
(B) Letter-identification tests 
1. Snellen’s letter chart test 
2. Sheridan’s letter test 
3. Flook’s symbol test 
4. Lipman’s HOTV test 
(C) Picture identification charts (miniature toy test) 
1. Allen’s picture cards test 
2. Beale Collin’s picture charts test 
3. Domino cards test 
4. Lighthouse test 
5. Minature toy test of Sheridan 
(D) Test based on picture identification on behavioural pattern 
1. Cardiff acuity cards test 
2. Bailey Hall cereal test 
 
III.  Resolution acuity tests 
1. Optokinetic nystagmus (OKN) test 
2. Preferential looking test (PLT) 
I. Two-alternative forced choice(2-AFC) test 
II. Operant variation looking(OPL) test 
 
 
 
 
III. Teller acuity cards(TAC) test 
       3.   Visually evoked response (VER) 
MEASUREMENT OF VISUAL ACUITY IN SCHOOL CHILDREN 
(ABOVE 5 YEARS) AND ADULTS33,34 
Snellen’s test  
It consists of black capital letters on white background arranged in 
series of descending size in lines.the lines of each letter measure an angle of 
one minute of arc in visual field. These lines fit into a square each measured 
at an angle of five minutes of arc. 
Landolt’s test  
It is similar to Snellen’s test types except that in it instead of the letter 
the broken circles are used. Each broken ring measures an angle of 5 minutes 
of arc and is constructed similar to letter of Snellen’s est types  
With Snellen’s letters, the end point consists of letter recognition; with 
Landolts’s rings, it consists of the detection of the orientation of the break in 
the circle. Each method has advantages and disadvantages. Letter targets 
represent a practical visual test. However, the ability to recognize the target is 
influenced by literacy and past experience, even if the targets are somewhat 
blurred. Landolt’s rings were designed to eliminate these factors and present 
a more objective test. However, since the gap can be placed in only four 
 
 
 
 
positions (up, down, left and right) guessing becomes an important factor. 
Also letter test remain much less confusing for the patient and the examiner, 
since the identification of letters is both immediate and unequivocal. 
Procedure of testing 
It is usually measured at a distance of 6 metres.so,that light rays falls 
parallel to eye and there will be less accommodation.The visual acuity is 
tested in each eyes and the values are recorded.it is recorded as 
6/6,6/9,6/12,6/18,6/24,6/36,6/60.If the subject is not able to read top line then 
it is recorded at 5m,4m,3m,2m,1m.If the subject is unable to red from 
1m,then he or she is asked to count fingers of examiner.if not,then he or she 
is tested for hand movements.if not,finally we can check for perception of 
light and projection of rays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Visual acuity equivalents in different notations33,34 
MAR or 
minimum angle 
of resolution 
(minutes of arc) 
Snellen's Visual 
acuity (ft) & 
(m) 
Snell-
Sterling's 
Visual 
efficiency 
(%) 
Loss of 
central 
vision 
(%) 
Snellen's 
fraction 
acuity 
relative 
Log 
acuity 
relative 
to 20/20 
0.5 20/10 6/3 109 0 2.0 0.3 
0.75 20/15 6/4.5 104 0 1.33 0.1 
1.00 20/20 6/6 100 0 1.0 0 
1.25 20/25 6/7.5 96 4 0.8 -0.1 
1.5 20/30 6/9 91 9 0.67 -0.18 
2.0 20/40 6/12 84 16 0.5 -0.3 
2.5 20/50 6/15 76 24 0.4 -0.4 
3.0 20/60 6/18 70 30 0.33 -0.5 
4.0 20/80 6/24 58 40 0.25 -0.6 
5.0 20/100 6/30 49 50 0.2 -0.7 
6.0 20/120 6/36 41 60 0.17 -0.78 
7.5 20/150 6/45 31 70 0.133 -0.88 
10.0 20/200 6/60 20 80 0.1. -1 
20.0 20/400 6/120 3 90 0.05 -1.3 
       
 
 
 
 
 
 
 
 
 
 
Type of Acuity Tasks: 
The detections of target requires perception of stimulus.The stimulus 
may be different.Some examples are 
 
a)bright object on dark background b)Dark object on bright background 
 
 
 
a)Landolt C  b)Illiterate E 
 
 
 
 
 
Task recognition by naming the letters in Snellen’s chart 
Snellen’s Notatation is given by   
VA=D/d 
VA-Visual acuity:D-Distance at which letters are read by the subject;d-
Distance at which normal person is able to see. 
Each snellen letter is subtended at an angle of 5 minutes of arc at a distance 
of 6 metres 
 
 
 
 
 
 
“Each stroke of Snellen letter subtends at an angle of one minute of arc.The 
reciprocal of snellen’s equation canbe given in angles as minutes of arc i.e., 
Minimum Angle of Resolution(MAR)” as stated by Adler’s .the log10 of 
MAR is LogMAR 
 
 
 
 
Snellen’s notation and conversion to spatial frequency 
 
 
 
 
 
Point spread function in different refractive stages of Eye 
 
 
MEAUREMENT OF VISUAL ACUITY IN PRESCHOOL CHILDREN 
1. Illiterate E-cutout test 
2. Tumbling E-pad test 
3. Isolated hand-figure test 
4. Sheridan Gardiner HOTV test 
5. Pictorial vision charts 
6. Broken wheel test 
 
 
 
 
7. Boek candy bead test 
8. Light home picture cards 
 
VISION TESTS IN 2-3 YEARS 
1. Dot visual acuity test 
2. Coin test 
3. Miniature toy test 
 
VISION TESTS IN  1-2 YEARS 
1. Marble game test 
2. Sheridan’s Ball test 
 
MEASUREMENT OF VISUAL ACUITY IN INFANTS33,34 
1. Optokinetic nystagmus (OKN) test 
2. Preferential looking test (PLT) 
3. Visual evoked response (VER) 
4. Catford drum test 
5. Cardiff acuity cards test 
6. Indirect assessment of visual acuity 
I. Blink reflex in response to sound is present since birth 
 
 
 
 
II. Menace reflex, i.e. reflex closure of the eyes on the approach of an 
object is usually present after the age of 5 months, if vision is normal. 
III. Test based on fixation reflex are useful in making a rough estimate of 
vision in infants. 
 
These include: 
· Fixation behavior test 
· Binocular fixation pattern 
· Central, Steady and maintained (CSM) method of rating monocular 
fixation 
 
MEASUREMENT OF VISUAL ACUITY FOR NEAR33,34 
Near vision is measured with the help of various types of Near Vision 
charts.It consists of different size of letters arranged in decreasing order 
Near vision charts are 
1. Jaeger’s Chart 
       Jaeger, in 1867, devised the near vision chart that consisted of 
the ordinary printer’s fonts of varying sizes used at that time. 
Printer’s fonts have changed  considerably since then; however. It is 
now a general custom to use various sizes of modern fonts that 
 
 
 
 
approximate Jaeger’s original choice.It is recorded as 
J1,J2,J3,J4,J5,J6,J7 
2. Roman test types. 
   To create a standard near vision chart,roman type was created by 
using Times new roman fonts instead of modern fonts. 
3. Snellen’s near vision test types.  
    It uses  same principles as in distant types. It is adjusted to about 
1/17th of the distant chart letters.  
The unusual configuration of letters of this chart, however, cannot be 
constructed from the available printer’s fonts. It can only be reproduced by a 
photographic reduction of the standard Snellen’s distant-vision test types to 
approximately 1/17th of their normal size. Further, such a test has never 
become popular. The graded sizes of pleasing types of passages from 
literature, the reading of which helps in the interpretation, are habitually 
employed. 
Procedure of testing 
It is tested at a distance of 25-35 cms, under better illumination thrown 
over his or her left shoulder. Each eye should be tested separately. The near 
vision is recorded as the smallest type that can be read comfortably by the 
 
 
 
 
patient. A note of the approximate distance at which the near-vision chart is 
held should also be made 
 
CONTRAST SENSITIVITY33,34,37,40,41,42 
INTRODUCTION 
It is defined as the ability of eye to differentiate variance in luminance 
level which are not separated by well defined borders and to appreciate sharp 
outlines of small objects.Previously it is measured with snellen’s test(high 
contrast).In many ocular disese,reduced contrast sensitivity is more important 
and disturbing than loss of visual acuity.It is less even if the subject has 6/6 
vision in both eyes.Contrast sensitivity relatively measures the function of 
retina. 
TYPES OF CONTRAST SENSITIVITY 
1. Spatial contrast sensitivity 
Spatial contrast sensitivity refers to detection of striped patterns at 
various levels luminance and frequencies. In its measurement, patient is 
presented with sine wave gratings of parallel light and dark bands ( Arden 
gratings) and is asked to tell the minimum contrast at which the a bars can be 
seen at seen at each frequency. The width of the bars is defined as spatial 
 
 
 
 
frequency which expresses the number of pairs of dark and light bars 
subtending an angle of 1 at the eye. A high spatial frequency implied narrow 
bars, whereas a low spatial frequency indicate wide bars.  
 
 
Spatial frequency measured in number of cycles per degree a)one cycle 
per degree b)two cycles per degree 
 
 
 
 
 
Photopic Contrast sensitivity function 
2. Temporal contrast sensitivity 
Here the contrast sensitivity function is generated for time-related 
(temporal) processing in the visual system by presenting a uniform target 
field modulated sinusoidal in time, rather than as a function of spatial 
position. 
Both temporal and spatial contrast sensitivity testing yield significantly 
more complete and systematic data on the status of visual performance 
thanthe conventional test. 
 
 
 
 
 
Contrast sensitivity in different ocular conditionsA-NormalB-Multiple 
sclerosis,C-Cataract,D-Amblyopia 
 
MEASUREMENT OFCONTRAST SENSITIVITY33,34 
When a subject is presented with the grating frequencies and contrast 
below which resolution is impossible, it indicates the threshold level; and the 
reciprocal of this threshold level is the contrast sensitivity. 
Contrast sensitivity is calculated  as “ (Lmax  - Lmin)/(Lmax  + Lmin )”, where L 
is the luminance  
 
 
 
 
VARIABLES IN THE MEASUREMENT 
There are three variables in the measurement of contrast sensitivity: 
I. Average amount of light reflected depends on illumination of paper 
and darkness of ink. 
II. Degree of blackness in relation to the white background, i.e. contrast. 
III. Various levels of cycles per degree of visual angle. 
 
METHODS OF MEASUREMENT 
Various methods have been developed to measure contrast sensitivity. 
Bodis Wollner, introducing contrast sensitivity measurement in clinical 
practice, suggested the name visuogram, analogue to an audiogram, to 
describe a patient’s contrast sensitivity curve’. The deficits were expressed in 
terms of decibles, and three types of deficits were described: 
1. High-frequency type characterized by increasing loss at high 
frequency. 
2. A level-loss type characterized by a similar loss for all spatial 
frequencies. 
3. A selective-loss type characterized by deficits of spatial frequencies in 
a narrow band. 
 
 
 
 
 
In general, the methods recommended to measure contrast sensitivity 
include: simple plates, cathode ray tube display on a screen, letter acuity 
charts, laser interferometer (LI) which produces grating on the retina, visual 
field testing using low contrast rings on stimuli, pattern discrimination test, 
prototype for forced choice printed test, visually evoked cortical potentials to 
checkerboard pattern reversal dependent contrast threshold measurement, 
two-alternative forced choice test and many more. 
Some of the simple, inexpensive but reliable methods of measuring 
contrast sensitivity are described in brief in the following text. 
1. Arden gratings test41 
Arden, in 1978. Introduced a booklet containing seven plates: one screening 
plate (No.1) and six diagnostic plates (No. 2-7 ). The contrast changes at the 
rate of 1.76 log units. The plates are studied at 57 cm, with spatial frequency 
increasing from 0.2 cycles/degree to 6.4 cycles/degree to 6.4 cycles/degree, 
each being double the frequency of the previous one. A score of 1-20 is 
assigned to each plate, depending upon the amount of plate uncovered. Sum 
of six plates will give a score of 82.It is highly normal for normal individuals.  
2. Cambridge low-contrast grating test33,34 
Cambridge low-contrast gratings consist of a set of ten plates 
containing gratings in a spiralbound booklet. To perform the test the booklet 
 
 
 
 
is hung on a wall at a distance of 6 m. The pages are presented in pairs, one 
above the other. One page in each pair contains gratings and the other is 
blank, but the pages have the same mean reflectance. The subject is simply 
required to choose which page, top or bottom, contains the grating. The pages 
are shown in order of descending contrast and are stopped when the first error 
is made. Four descending series are shown separately to each eye. When no 
error is made at plate 10, then a score of 11 is given. Depending upon the 
total score of the patient from four series, the contrast sensitivity is noted 
from the conversion table. 
3. Pelli-Robson contrast sensitivity chart42 
This chart consists of letters that subtend an angle of 3 at a distance of 
1 m. The chart is printed on both the sides. The two sides will have different 
size of  letters. The letters on chart are organized as triplets, there being two 
triplets in each line. The contrast value decreases from one triple to other. 
The log contrast sensitivity range  from 0.00 to 2.25. 
To perform the test, the chart is hung on the wall, so that its centre is 
approximately at the level of the subject’s eye as possible, so that the 
luminance is set at level of 60 and 120 cd/m2.The luminance is determined 
with the help of a light meter. 
 
 
 
 
While recording, the subject sits directly in front of the chart at a distance of 
1 m (with the best distance correction). The subject is made to name or 
outline each letter on the chart, starting from the upper to lower line by 
reading across horizontally . Subject is made to guess, even when he or she 
believes that the letters are invisible. The test is concluded when the subject 
guesses two of the three letters of the triplet incorrectly.the score is given if 
he or she read two or three letters correctly. 
4. The Vistech chart 
 This chart consists of sine wave gratings and is used at a distance 
of 3 m from the subject. In this test, contrast is assessed at several spatial 
frequencies (distance of the separation of the grating bars) and the subject has 
to identify the orientation of the grating, i.e. whether vertical or 15 clockwise, 
or anticlockwise.  
5.Functional Acuity Contrast Test62,63: 
It  was first developed by Dr.Arthur.P.Ginsburg,who is the pioneer 
in contrast sensitivity technology.It offers more sensitive and comprehensive 
measure functional vision than standard Snellen acuity. 
Normal snellen acuity tests only the high contrast letters.It is  for 
detecting refractive errors but it fails to analyse early visual loss due to 
glaucoma,cataract,macular and retinal dysfunction,optic nerve disease etc., 
 
 
 
 
Real world doesn’t have only high contrast black and white.Rather ,it 
consists of  different conditions such as fog,nighttime,bright sun etc.,Many 
visual disorders will show significant visual loss under these conditions. 
It is measured using Stereoptical Optec 6500P FVA® 
It was done with illumination as recommended by the manufacturer 
It has sine wave gratings with stepwise increase in size .It has five rows 
A,B,C,D and E with corresponding spatial frequencies 1.5,3,6,12 and 18 
cycles per degree(cpd) respectively. 
The contrast between each grating is 0.15 log units. 
Glare were produced by light source with in the instrument.luminance used 
as recommended by manufacturer.  
The patient is shown the rows A,B,C,D and E.Each row  will have nine 
responses.the responses were recorded for each rows. 
 The values are first recorded for individual eyes and then for both eyes in 
day and night situations,with and without glare. 
The values are recorded in FACT recording form. 
The values are converted to Logirthamic contrast values 
 
 
 
 
 
 
 
 
 
 
 
The tests to measure disability glare are: 
1.Miller-Nadler Glare test 
2.Brightness acuity test 
3.Vistech MCT8000 test 
4.Stereoptical Optec 6500P FVA 
NEURAL MECHANISMS OF CONTRAST SENSITIVITY 
Campbell and Green43 stated that” the concept of different visual 
channels for handling information about different bands if spatial 
frequencies. This concept indicates that retina is non-uniform; Fovea is 
specialized for high acuity and is responsible for high spatial frequencies. In 
the retinal periphery, only low-frequency channels are represented. For 
coarse gratings, central and peripheral retina have equal contrast sensitivity 
GLARE: 
The bright light will be  uncomfortable to person  and it may lead to loss of 
visual function known as disability glare.It is due to excessive scatter 
produced by bright light. 
Clinically it measured by reduced visual acuity or contrast sensivity with 
external glare source. 
 
 
 
 
per unit area of retina, but the larger the retinal area  stimulated the grater is 
the sensitivity, Thus, contrast sensitivity will be reduced in peripheral retinal 
diseases, and the use of low-frequency grating would provide rapid check of 
peripheral retinal function.” 
Further, Campbell and Robson43 proposed that “ the existence of linearly 
operating independent mechanisms within the nervous system which are 
selectively sensitive to the orientation to limited range of spatial frequencies. 
The orientation selectivity and the interocular transfer of the adaptation effect 
implicated the visual cortex as the site of these neurons. They attempted to 
explain the preliminary and essential role of such interactions in the 
recognition of complex images and generalization for magnifications.” 
FACTORS AFFECTING CONTRAT SENSITIVITY33,34 
1. Refractive errors. the refractive errors affect only the higher frequencies. 
2. Age. There occurs a definite decrease in contrast sensitivity with 
increasing age.  
3. Lenticular changes. Early lens changes can reduce contrast sensitivity 
essentially for low spatial frequencies. This decrease in contrast sensitivity is 
not related to visual acuity. 
4. Ocular and systemic diseases. Contrast sensitivity is also found to be 
affected by various ophthalmic as well as systemic diseases. It is decreased in 
 
 
 
 
cases with retinal, optic nerve and visual pathway diseases, glaucoma, ocular 
hypertension, retrobulbar neuritis, multiple sclerosis, amblyopia, diabetes 
mellitus, pituitary adenoma, etc. 
DIAGNOSTIC APPLICATIONS 
The contrast sensitivity function, in recent years, has become popular 
as a possible diagnostic indicator of visual function. Deviations from normal 
standards have been reported in a number of conditions; some of which are 
listed above. It has been reported that contrast sensitivity (modulation transfer 
functions) may provide a fairly complete statement of the relations among 
spatial frequency or the fineness of visual details, the contrast required for 
resolution of detail and the luminance of the stimulus. 
TESTS FOR POTENTIAL VISION33,34 
Tests for potential vision have been developed in an effort to determine 
whether the individuals with obvious impaired vision have a potential to see 
well after the cataract surgery (i.e. whether the significant cause of their 
visual impairment is cataract of any other associated retinal pathology). 
Various subjective and objective tests are available for this purpose. 
Interferometry and potential acuity meter (PAM) tests are currently the most 
popular one and it is said to be the most accurate in predicting visual acuity in 
patients with cataracts 
 
 
 
 
VISUAL ADAPTATIONS 
The level at which light can just barely be detected is only one billionth 
of the level at which exposure to light may cause injury.There is different 
level of illuminaton in normal life,human eye has to adapt and function 
normally.It has both light and dark adaptation . The terms light and dark 
adaptation are relative and indicate the change in sensitivity which the retina 
is making, rather than any static condition. For example, if the illumination in 
a room is that of  moderate daylight than and a room is that of moderate 
daylight and person goes not into the sunshine, his retina undergoes light 
adaptation. On the contrary, if the person form same room with moderate day 
light illumination goes into a dark room, his retina under goes dark 
adaptation. The change which takes place is always that which best enables 
the retina to function under the new condition. 
 
DARK ADAPTATION53,54,57  
The power of eye to adjust itself to decreasing order of illumination is 
called dark adaptation.the taken to adapt eye to see in dim illumination is 
called dark adaptation time.Rods are the principle sensitive organs of dim 
illumination.The rods are used in scotopic vision and cones in photopic 
vision. 
 
 
 
 
Dark Adaptation Curve: 
 
 
 
To get a Dark-Adaptation Curve,subject is pre adapted to light for 5 minutes, 
then threshold is measured over time.Initially there is rapid decline in 
threshold followed by slow decline 
 
 
 
 
 
Temporal summation: Bloch's law of vision56,61 
 The completely dark adapted retina needs to absorb - several quanta of 
light within a restricted time and area before a sensation can be elicited. The 
critical period of temporal summation is about 0.1 seconds. During this 
period, a given amount of luminous energy will have the same effect, 
regardless of its distribution in time. This is Bloch's law, which can be 
expressed as Bt - k, where B is the luminance.t- the duration of the. stimulus, 
and k a constant. Beyond the critical duration, temporal summation does not 
occur and the effect of a test light becomes dependant on its luminance alone. 
The critical period varies with stimulus size, background luminance, the type 
of task (about 0.1 s for detection, 0.4 s for discrimination) and wavelength 
(about 0.25 s for blue targets, 0.1 s for red.  
 
The Broca-Sulzer and Troxler effects 56,61 
 The Broca-Sulzer effect,when a light is turned on, there is a critical 
period during which its apparent brightness undergoes temporal summation; 
the apparent brightness falls to a plateau once the critical period has expired. 
This is why a short flash (shorter than the critical period, so that no plateau is 
reached) can appear brighter than a longer flash of the same luminance. This 
is the Broca-Sulzer effect.  
 
 
 
 
The Troxler effect. It occurs when a spot of light is projected on to the 
retina and held completely stationary. The light appears to fade away and 
disappears, and because this can occur without the bleaching of an 
appreciable fraction of retinal photopigment, a neural rather than 
photochemical mechanism is likely.  
Factors influencing Dark Adaptation54 
1. Luminance (intensity) of the preadapting light  
2. Duration of the light used to preadapt the eye  
3. Energy of the light used to preadapt the eye  
4. Wavelength distribution (colour) of the adapting light  
5. Wavelength (colour) of the test stimulus  
6. Duration of exposure of retina to test flash  
7. Region of the retina where test stimulus is applied  
8. Vitamin A deficiency  
9. Effects of anoxia on dark adaptation  
10. Effect of tobacco inhalation  
11. Effect of anaesthesia on dark adaptation  
12. Effect of opacities in ocular media on the dark adaptation curve  
13. Dark adaptation in retinal degenerations  
14. Dark adaptation in myopia 
15. Dark adaptation in glaucoma  
 
 
 
 
LIGHT ADAPTATION55,56 
 When a person moves from dim to bright light eye adapts itself to 
increasing order of illumination by changes in the retinal sensitivity called 
Light adaptation. 
The visual system must detect contrast over a huge range of light 
intensities at least 12 log units. The area of the pupil can vary only 16-fold 
(1.3 log units) and therefore its role in visual adaptation is limited. Light 
adaptation is a form of "automatic gain control". Over a range of at least 3 log 
units of cone function, the intensity increment required for detection, DI, 
where DI/I is a constant, is known as the Weber-Fechner relation, and the 
constant is called the Weber fraction. The relationship breaks down at higher 
light levels, when saturation occurs. Light adaptation works very quickly, 
gets faster as background intensity increases and is dependent on calcium Ion 
flux; it is abolished when calcium is buffered inside photoreceptors. The light 
adapted eye is maximally sensitive at about 555 nm.  
Time course of Light adaptation are 
1.Anticipatory effect 
2.Transient effect 
3.Photochemical effect 
 
 
 
 
 
COLOUR VISION33,34 
It is the ability of eye to differentiate colours in different 
wavelengths.Some broad facts about colour vision are as follows: 
· Colour vision is the inherited property of cones(photopic vision). 
· Colour is a perceptual phenomenon, not just a physical property of an 
object. Many factors determine the colour perceived: the spectral com- 
position of light from the object is important, but the spectral 
composition of light from the visual surroundings and the state of light 
adaptation of the eye also contributes. 
·  The sensation of colour is subjective. Individuals are taught names for 
their colour sensations and subsequently use these names whenever the 
same  sensation is obtained. 
· There are three different types of cones viz. red sensitive, green 
sensitive and blue sensitive, which combinedly perform the function of 
colour vision. 
· All colours are a result of admixture in different proportion of three 
primary colours: the red (723- 647 nm), green (575-492 nm) and blue 
(392-450 nm). 
·  Colours have three attributes: hue, intensity and saturation. 
· For any colour there is a complementary colour that, when properly 
mixed with it, produces a sensation of white. 
 
 
 
 
· The colour perceived depends up on the background of object. 
· A normal person can see all wavelengths between violet to red. If the 
wavelength is shorter than that of violet, the light becomes ultraviolet 
(UV) and is beyond visibility. If the wavelength is greater than 750 
nm, the light is infrared and is again beyond visibility. Human beings 
could have seen even UV light as blue cones retain some sensitivity at 
around 10 nm, but crystalline lens blocks all UV rays.Consequently, 
after cataract operation, one can see the UV rays to some extent. 
· In, dim light,colours appear as gray; that is called Purkinje shift 
phenomenon. 
Theories of colour vision48,49 
1.Trichromatic theory 
2.Opponent theory of Herring 
Tests for colour vision33,34: 
1. Pseudo isochromatic chart test 
2. Hardy rand rittler test 
3. The lantern test 
4. Fransworth-Munsell 100 hue test 
5. City University colour vision test 
6. Nagels anomaloscope test 
7. Holmgrens wool test 
 
 
 
 
8. D-15 test 
9. PV-16 test 
10. Lantorn test 
11. The new colour test 
12. Colour vision testing made easy 
DEVELOPMENT OF IND-VFQ3364,65 
“Development of The Indian Vision function questionnaire: field 
testing and psychometric evaluation” by RD Thulasiraj et al64 
For the development of IND-VFQ33,Patients with eye diseases like 
cataract, glaucoma, diabetic retinopathy and age related macular degeneration  
were recruited from leading eye hospitals in three centres in India (Delhi, 
Hyderabad and Madurai) 
Their main objective was to develop and evaluate the validity, 
responsiveness, repeatability, accuracy of questionnaire 
It is a 33 item questionnaire (IND-VFQ33) which addresses patient visual 
problems  in real life activities. 
It is an interviewer administered questionnaire.Questionnaire items 
included are 
 “1.General functioning scale 
 
 
 
 
            2.Psychosocial impact scale 
            3.Visual symptoms scale” 
S K Gupta et al stated that “It showed better convergent validity compared 
to visual acuity 
It produces separate summary scores for each scale rather than total 
score Responsiveness were directed to cataract patients since cataract surgery 
provides clear intervention of known efficacy compared to other diseases 
They showed that IND-VFQ33 was practically,scientifically good 
measure to evaluate vision related quality of  life in clinical studies,drug trials 
and in epidemiological studies in South Asia 
Further modifications of IND-VFQ require changes in content,format 
and translation in to other languages” 
VALIDTION OF IND-VFQ33: 
“The Impact Of Severity of Vision loss on Vision-related Quality of 
life in India: An evaluation of The IND-VFQ33)” by RP Finger et al70 
It is the cross-sectional, observational study done in cataract patients enrolled 
from One of the south Indian eye hospital 
Their objective was to evaluate IND-VFQ33  questionnaire  and 
identify the correlation between Vision impairement and Quality of life 
 
 
 
 
Instead of three scales as used in IND-VFQ33, “they used four scales 
general functioning scale with vision specific mobility,activity 
limitation,psychosocial scale,visual symptoms scale” 
They studied visual impairment as mild,moderate,severe 
They found “ severe visual impairment and blindness is directly associated 
with vision specific mobility and activity limitation” 
Mild visual impairment is not related to reduction in vision functioning 
They didn’t found association between vision disability and emotional level 
as mentioned in many studies 
Their four  sub-scales showed accurate targetting and suggests that patients 
had higher ability  in perfoming than with three scales 
They concluded that IND-VFQ33 is a valid questionnaire to assess quality of 
life related to vision problems 
 
 
 
 
 
 
 
 
 
LITERATURE REVIEW 
1.Gariner AM et al studied “the relation between visual function and 
visual daiasbility in uveitis patients”75 
            This is one of the very few studies done to assess visual function in 
Uveitis patients.132 patients of uveitis were enrolled to the study.They 
compared the low and high contrast visual acuity  by Log MAR letters using 
a Bailey-Love chart and contrast sensitivity with vision related quality of life 
assessed using Vision specific Quality Of Life (VQOL) questionnaire.they 
studied both monocularly and binocularly 
         The study concluded that Binocular contrast sensitivity is the best 
measure to measure the visual function in uveitis patients  in real 
situations.the young patients with poor binocular visual acuity had worst 
quality of life 
2.Rhelt M et al studied “ the visual function and general health status in 
apatients with uveitis”72 
         This study has been done at National Eye Institute,Bethesda using the 
most popular – “the medical outcomes study 36,Item short form (SF-36) and 
National Eye Institute Visual function questionnaire (NEI VFQ-25)”.The 
study assessed and compared visual function with the general health status in 
patients with uveitis and normal population.Visual acuity and type of uveitis 
 
 
 
 
and treatment offered were also noted.Patient’s co-morbidity was also 
assessed. 
Overall 76 patients were included.The NEI VFQ-25 score was 
significantly lower among patients with uveitis than in the normal 
population(p<0.001).Visual acuity,Binocular involvement,type of therapy 
and SF36 Physical (PCS) and Mental(MCS) component summary scores 
were all significantly associated with overall NEI VFQ-25 scores in 
multivariate analysis. 
   This study revealed that uveitis affects the visual functioning and general 
health of the patients.More severe the disease more pronounced is the fall in 
visual functioning scores. 
           The both visual function and general health status measure contribute 
additional information and both should be performed in uveitis patients to 
measure the effectiveness of therapy and disease 
3.Shiela T.Angeles-Han et al studied  “the visual function and quality of 
life in children with uveitis”77 
In this study they analysed the impact of physical and visual disability on 
QOLin children with and without uveitis in Juvenile idiopathic Arthritis(JIA). 
The QOL questionnaire were administered to 27 children to measure physical 
and visual function. 
 
 
 
 
They concluded that visual impairment is an important tool to measure QOL 
in children with JIA uveitis.They also suggest to include visual and physical 
function in quality of life assessment in children with uveitis. 
4.C C Murphy et al studied “ the visual function and quality of life in 
intermediate uveitis”76 
In this study they assessed visual function and Vision related quality of 
life(VR-QOL) and general health related quality of life(HR-QOL) in 
Intermediate Uveitis 
In 42 patients,VR-QOL and HR-QOL evaluated using VCM1 and SF-36 
questionnaires respectively.Log MAR visual acuity,Pelli-Robson Contrast 
sensitivity Farnsworth-Munsell 100 Hue colour vision and Estermann visual 
field were recorded monocularly and binocularly. 
They concluded that majority of patients with Intermediate Uveitis maintain 
god visual function and quality of life.Impaired VR-QOL and HR-QOL 
correlates with worse eye with Intermediate Uveitis. 
5.Janine Scherrer et al studied “the visual function in toxoplasmosis 
associated uveitis”78 
In this study they assessed visual function with visual acuity and visual fields. 
 
 
 
 
They studied 61 patients with inactive state Toxoplasmosis. Ophthalmic 
examination,Fundus photography and Octopus perimetry  were done in each 
patients. 
They have concluded that “ in Inactive Ocular Toxoplasmosis , permanent 
visual field defects seen in >94% of the eyes.Standard automated perimetry 
may better reflect the functional damage than visual acuity”. 
 
6.Arvind venkatraman et al studied “A pre and post treatment 
evaluation of quality of life in patients with Uveitis”79 
They studied the effect of treatment on vision-related quality of life (VR-
QOL) in uveitis patients 
They showed that chronic uveitis had better improvement in visual ability 
compared to acute uveitis. 
They conclude that VR-QOL measure showed greater sensitivity in 
determining disability of patients compared to the clinical or demographic 
details and also there is a high correlation between the visual acuity and 
quality of life in uveitis in response to the treatment. 
 
 
 
 
 
 
                    AIMS AND OBJECTIVES 
The Aim of the study is  
1. To assess the visual function in patients with uveitis by measuring 
Visual acuity,Contrast sensitivity(Day or Photopic) and (Night or 
scotopic),both measured with and without Glare,Monocularly and 
binocularly (Pre and Post treatment). 
 
2. To assess the Vision related Quality of Life(VR-QOL) in patients with 
uveitis(Pre and Post treatment) using IND-VFQ33 Questionnaire. 
 
3. To Correlate the assessed Visual function with Vision related related 
Quality of Life(VR-QOL) in patients with uveitis(Pre and Post 
treatment). 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
Study design: 
Single centre,single examiner /interviewer based Prospective study   
Study Place: 
                    Uveitis clinic 
Study period:  
Between September 2013 and August 2014 
Approval: 
The study was approved by Hospital ethics committee  
 
Inclusion Criteria: 
     Age 16 years and above 
     Newly diagnosed case of uveitis 
     Patient who were able to perform the test. 
     Patient who are willing to participate. 
 
 
 
 
 
 
 
Exclusion criteria: 
    Age less than 16 years. 
    Patients who were previously diagnosed as a case of uveitis and  on 
treatment. 
    Patient who are unable to perform the test. 
    Patients with pre-existing ocular conditions like Cataract,Diabetic 
retinopathy, ARMD and other macular disorders, Retinal detinal detachment, 
glaucoma, optic nerve disorders, corneal pathology, amblyopia, low vision 
etc., 
   Patient with history of refractive surgical procedures like LASIK,       
Femto LASIKetc.,and  Vitreo-retinal surgeries. 
   Patient having speech or hearing problems.and who have non-visual 
physical disabilities. 
  Patient who are not turned for follow up. 
Age group of 16 and above were selected,since the questionnaire has been 
developed for the adult population. 
 
 
 
 
The patients who have unilateral or bilateral disease either Anterior 
uveitis,Intermediate uveitis,posterior uveitis or Pan uveitis were included in 
the study 
The patients included in the study were explained in detail about the 
study,questionnaires and purpose. 
All the patients were thoroughly examined,refraction done for all 
patient to find out Best Corrected Visual Acuity and other ocular examination 
include Intraocular pressure measurement,Slit lamp examination +90 D 
Fundus examination and Indirect ophthalmoscope examination and 
investigations necessary for diagnosis were done.Demographic,Clinical 
examination details were recorded in data sheet. 
Contrast sensitivity  and Vision related quality of life assessment were 
assessed after the confirmation of diagnosis.If the patients  requires mydriatic 
and cycloplegics,the tests were carried out in the same conditions.these were 
assessed in patients under real time situations. 
Treatment given were also recorded. 
Patient was advised to come for follow up in about one month,there 
were variation on situation warranted but the response was recorded during 
the visit around one month time. 
 
 
 
 
The patient who came for follow up were examined.Best Corrected 
Visual acuity,Contrast sensitivity and vision related Quality of life (VR-
QOL) were assessed in similar fashion which was done before the 
commencement of treatment. 
Patients were asked whether they were using medications regularly as 
per the advise. 
If need the therapy was modified or withdrawn as the individual cases 
needed. 
A new case of uveitis is defined as one with no previous treatment with 
topical,systemic steroids or immunosupressions,because visual function and 
quality of life could have been very much altered by the therapeutic 
intervention,however they need to be excluded. 
Patients who were unable to read the letters in snellen’s chart in one or 
both eyes were excluded. 
Patients with other ocular conditions like cataract,diabetic 
retinopathy,macular disorders etc., will significantly affect the test were 
excluded. 
Patients with previous history of refractive procedures like LASIK etc., 
and Vitreo-retinal surgeries will significantly affect the test were excluded. 
 
 
 
 
Patients who have physical disability,speech or hearing problems were 
excluded. 
Patients who are not willing to participate,not willing for followup were 
excluded. 
Clinical Examination: 
A detailed clinical examination  and investigations  as mentioned was 
done and anatomical diagnosis was arrived as Anterior uveitis or 
Intermediate uveitis or Posterior uveitis or Panuveitis. 
Visual function Assessment: 
Visual function assessed are Visual Acuity(VA) and Contrast 
Sensitivity(Day) and Contrast sensitivity(Night) measured both with and 
without glare .these were assessed after best corrected spectacle correction .it 
was done first monocularly then binocularly. 
Visual Acuity(VA) 
Visual acuity was measured using Standard Snellen’s chart at 3 metre 
distance.Refraction was done.Best corrected Visual Acuity(BCVA) was 
measured in individual eyes .It was recorded in Snellen’s notation and was 
converted in to LogMAR equivalents. 
 
 
 
 
 
Contrast Sensitivity(CS) 
Contrast Sensitivity for distant vision was measured in day(photopic) 
and night (scotopic) situations.Both day and night contrast sensitivity were 
assessed with glare and without glare.It was first done in individual eyes and 
then both eyes. 
Contrast Sensitivity(CS) was measured by Functional Acuity Contrast 
Test using Stereoptical Optec 6500P FVA®.It was done with illumination 
as recommended by the manufacturer 
It has sine wave gratings with stepwise increase in size .It has five 
rows A,B,C,D and E with corresponding spatial frequencies 1.5,3,6,12 and 
18 cycles per degree(cpd) respectively.The contrast between each grating is 
0.15 log units.Glare were produced by light source with in the 
instrument.luminance used as recommended by manufacturer. The patient is 
shown the rows A,B,C,D and E.Each row will have nine responses.The 
responses were recorded for each rows. 
 The values are first recorded for individual eyes and then for both eyes 
in day and night situations,with and without glare.The values are recorded in 
Functional Acuity Contrast Test(FACT) recording form(Annexed). 
The values are converted to Logirthamic contrast values.The values 
are entered in to the Data sheet. 
 
 
 
 
Vision related quality of life Assessment: 
It was assessed using  
Indian Visual Function Questionnaire 33(IND-VFQ 33).It is a 33 item 
questionnaire.It has three scales 
1.General functioning questions(question 1 to 21) 
2.Psychosocial questions(question 22 to 26) 
3.Visual symptoms questions(question 27 to 33) 
The questions were administered to patients by single interviewer.The 
response is recorded for each scale in th recording form. 
The response is recorded as follows: 
For General functioning scale: 
0-Not at all 
1-A little 
2-Quite a bit 
3-A lot 
4-Cannot do this because of my sight 
 
 
 
 
 
For Psychosocial impact and Visual symptoms scale: 
0-Not at all 
1-A little 
2-Quite a bit 
3-A lot 
The responses recorded in the form are entered in to the data sheet.It is done 
for pre and post treatment in patients with uveitis 
 
 
 
 
 
 
 
 
 
 
 
 
 
DATA ANALYSIS 
  Mean (SD) and Frequency (percentage) was used for continuous and 
categorical variables respectively. 
  Student t-test or Mann-whitney U test was used to test mean difference 
between the two continuous variables. 
   Paired t-test or Wilcoxon rank sum test was used to assess the difference 
between pre and post mean values.   
 P-value is less than 0.05 considered as statistically significant.  
 All statistical analysis was done by statistical software STATA 11.0.  
The values obtained are tabulated  
Graphs and charts made from tables  
 
 
 
 
 
 
 
 
 
DEMOGRAPHIC VALUES
54 patients were included in this study.108 eyes of 54 patients were studied
Age 
 Mean (SD) of the age
range is between 16 – 48 years
Eye 
Eye 
Right 
Left 
Total 
 
80 eyes out of 108 were affected.Right eye more affected compared to the 
left eye 
Sex 
Sex 
Male 
Female 
Total 
 
51.8%
 
RESULTS 
 
 at the presentation  is 32.31(8.04)years 
 
n % 
42 52.5 
28 47.5 
80 100.0 
n % 
26 48.2 
28 51.8 
54 100.0 
48.2%
Sex
Male Female
 
and the 
 
 
 
 
Laterality 
Laterality
Unilateral
Bilateral 
Total 
 
 
 
Uveitis is unilaterally affected in 28 patients 
patients 
 
 
48.2%
 
 n % 
 28 51.8 
26 48.2 
54 100.0 
and bilaterally affected in 26 
51.8%
Laterality
Unilateral Bilateral
 
 
 
 
Anatomical location 
Anatomical location
Anterior uveitis 
Intermediate uveitis
Posterior uveitis 
Panuveitis 
Unaffected eyes 
Total 
 
 
Panuveitis is most commonly affected followed by anterior uveitis,
intermediate uveitis and posterior uveitis
25.9%
25.9%
Anatomical Location
Anterior Intermediate
 
 n % 
23 21.3 
 17 15.7 
12 11.1 
28 25.9 
28 25.9 
108 100.0 
 
21.3%
15.7%
11.1%
Posterior Pan None
 
 
 
 
 
 
Pre and Post treatment evaluation of BCVA based on Anatomical 
location 
Anatomical 
location 
BCVA 
n Mean(SD) Log MAR 
Median 
(Snellen’s 
equivalent) 
Min – 
Max P-value 
Anterior uveitis 
     Pre treatment 
      
    Post treatment 
 
23 
 
23 
 
0.35(0.19) 
 
0.18(0.25) 
 
0.3(6/12) 
 
0.18(6/9) 
 
0.18 – 0.6 
 
0 – 0.78 
 
 
0.0051 
Intermediate 
uveitis 
      Pre treatment 
    
    Post treatment 
 
 
17 
 
17 
 
 
0.33(0.07) 
 
0.16(0.11) 
 
 
0.3(6/12) 
 
0.18(6/9) 
 
 
0.3 – 0.48 
 
0 – 0.48 
 
 
 
0.0002 
Posterior uveitis 
     Pre treatment 
 
     Post treatment 
 
12 
 
12 
 
0.42(0.16) 
 
0.31(0.16) 
 
0.39(6/15) 
 
0.3(6/12) 
 
0.18 – 0.6 
 
0 – 0.6 
 
 
0.1100 
Pan uveitis 
     Pre treatment 
      
   Post treatment 
 
28 
 
28 
 
0.57(0.16) 
 
0.53(0.27) 
 
0.54(6/24) 
 
0.6(6/24) 
 
0.3 – 0.78 
 
0.18 – 1  
 
 
0.5833 
Total  
    Pre treatment 
 
     Post treatment 
 
80 
 
80 
 
0.43(0.19) 
 
0.32(0.28) 
 
0.48(6/18) 
 
0.18(6/9) 
 
0 – 0.78 
 
0 – 1  
 
 
0.0001 
 
 
 
 
 
Assessment of Visual Acuity based on
 
Analysis of Best Corrected Visual acuity in uveitis based on anatomical 
location showed that there is a significant improvement in visual acuity post 
treatment in Anterior uveitis and Intermediate uveitis.
There is no significant impr
Posterior and panuveitis 
Overall there is an improvement in visual acuity post treatment
0.35
0.18
0.00
0.20
0.40
0.60
0.80
1.00
Anterior Uveitis
M
ea
n
Pre treatment
 
 Anatomical location
 
ovement in visual acuity post treatment in 
 
0.33
0.42
0.57
0.16
0.31
0.53
Intermediate 
Uveitis
Posterior Uveitis Pan Uveitis
BCVA 
Post treatment
 
 
 
 
 
 
Contrast sensitivity assessment (Day) in affected eyes 
Contrast 
sensitivity 
(Day) 
Pre treatment Post treatment 
P-value Mean(SD) Min – Max Mean(SD) Min – Max 
Without glare 
Spatial 
frequency 
      1.5 
      3 
      6  
      12 
      18 
 
 
1.29(0.16) 
1.46(0.20) 
1.47(0.21) 
1.29(0.21) 
0.94(0.36) 
 
 
1.11 – 1.7 
1.18 – 2.06 
1.2 – 2.11 
1.04 – 1.78 
0 – 1.52 
 
 
1.38(0.29) 
1.57(0.29) 
1.60(0.30) 
1.34(0.44) 
1.05(0.44) 
 
 
0.85 – 1.7 
1 – 2.06 
1.08 –2.11 
0 – 1.78 
0 – 1.52 
 
 
0.003 
0.007 
0.001 
0.286 
0.052 
With glare 
Spatial 
frequency 
      1.5 
      3 
      6  
      12 
      18 
 
 
1.23(0.20) 
1.39(0.22) 
1.42(0.23) 
1.09(0.44) 
0.83(0.43) 
 
 
0.95 – 1.7 
1 – 2.06 
1.08 – 2.11 
0 – 1.78 
0 – 1.52 
 
 
1.32(0.36) 
1.48(0.39) 
1.51(0.39) 
1.21(0.55) 
0.93(0.53) 
 
 
0 – 1.7 
0 – 2.06 
0 – 2.11 
0 – 1.78 
0 – 1.52 
 
 
0.030 
0.051 
0.024 
0.114 
0.164 
 
 
 
 
 
 
 
Contrast sensitivity(Day) without glare in affected eyes
 
 
The overall assessment of contrast sensitivity in day time situations with out 
glare with log contrast values  showed that there is significant improvement 
in spatial frequencies of 1.5,3,6 cpd  post treatment but there is no significant 
improvement in contrast sensitivity at higher spatial frequencies such as 12 
and 18 cpd 
 
 
1.29
1.461.38
0.0
1.0
2.0
3.0
1.5
M
ea
n
Contrast Sensitivity(Day) 
Without Glare
 
 
1.47
1.29
0.94
1.57 1.60
1.34
3 6 12 18
Spatial frequency
Pre treatment Post treatment
 
1.05
 
 
 
Contrast sensitivity(Day) with glare in affected eyes
 
 
The overall assessment of contrast sensitivity in day time situations with 
glare with log contrast values showed that there is no 
improvement in contrast sensitivity at all spatial frequencies.
In this condition contrast sensitivity at higher spatial frequencies such as 12 
and 18 are highly affected. 
 
 
1.23
1.391.32
0.0
1.0
2.0
3.0
1.5
M
ea
n
Contrast Sensitivity(Day) With Glare
 
 
significant 
 
1.42
1.09
0.83
1.48 1.51
1.21
0.93
3 6 12 18
Spatial frequency
Pre treatment Post treatment
 
 
 
 
 
Contrast sensitivity Assessment (Night) in affected eyes 
Contrast sensitivity 
(Night) 
Pre treatment Post treatment 
P-value Mean(SD) Min – 
Max 
Mean(SD) Min – 
Max 
Without glare 
Spatial frequency 
      1.5 
      3 
      6  
      12 
      18 
 
1.12(0.30) 
1.25(0.33) 
1.18(0.49) 
0.81(0.60) 
0.64(0.49) 
 
0 – 1.7 
0 – 2.06 
0 – 2.11 
0 – 1.78 
0 – 1.52 
 
1.13(0.57) 
1.20(0.72) 
1.21(0.73) 
1.04(0.68) 
0.86(0.54) 
 
0 – 1.7 
0 – 2.06 
0 – 2.11 
0 – 1.78 
0 – 1.52 
 
0.879 
0.468 
0.707 
0.013 
0.001 
With glare 
Spatial frequency 
      1.5 
      3 
      6  
      12 
      18 
 
0.98(0.43) 
1.00(0.52) 
0.85(0.67) 
0.51(0.63) 
0.38(0.51) 
 
0 – 1.7 
0 – 2.06 
0 – 2.11 
0 – 1.78 
0 – 1.52 
 
1.01(0.62) 
1.09(0.72) 
1.10(0.73) 
0.92(0.63) 
0.68(0.53) 
 
0 – 1.7 
0 – 2.06 
0 – 2.11 
0 – 1.78 
0 – 1.52 
 
0.604 
0.302 
0.006 
<0.001 
<0.001 
 
 
 
 
 
 
 
 
 
Contrast sensitivity
 
 
The overall assessment of contrast sensitivity in night time situations without 
glare with log contrast values showed that contrast sensitivity is highly 
affected at 1.5,3,and 6 cpd spatial frequencies but less affected 
spatial frequencies(12 and 18 cpd)
 
 
 
1.12
1.25
1.13
0.0
1.0
2.0
3.0
1.5
M
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n
Contrast Sensitivity(Night)
Without Glare
Pre treatment
 
 (Night) without glare in affected eyes
 
1.18
0.81
0.64
1.20 1.21
1.04
3 6 12 18
Spatial frequency
Post treatment
 
 
at higher 
0.86
 
 
 
Contrast sensitivity
 
 
The overall assessment of contrast sensitivity in night time situations without 
glare with log contrast values showed that contrast sensitivity is 
affected at1.5 and 3 cpd spatial frequencies but less affected at 6,12 and 18 
cpd spatial frequencies. 
So,contrast sensitivity in affected eyes showed that it is reduced in day light 
with glare  and night with and without glare in 1.5,3 and 6 cpd sp
frequencies. Higher spatial frequencies such as 12 and 18 cpd are least 
affected in night situations. 
0.98 1.001.01
0.0
1.0
2.0
3.0
1.5
M
ea
n
Contrast Sensitivity(Night)
With Glare
Pre treatment
 
 (Night) with glare in affected eyes 
0.85
0.51
0.38
1.09 1.10
0.92
3 6 12 18
Spatial frequency
Post treatment
 
highly 
atial 
0.68
 
 
 
 
Contrast sensitivity assessment (Day) in both eyes 
 
Contrast 
sensitivity 
(Day) 
Both eyes 
Pre treatment Post treatment 
P-
value 
Mean(SD) Min – Max Mean(SD) Min – Max 
Without glare 
Spatial 
frequency 
      1.5 
      3 
      6  
      12 
      18 
 
 
1.37(0.17) 
1.56(0.19) 
1.55(0.19) 
1.37(0.18) 
1.02(0.31) 
 
 
1.11 – 1.7 
1.18 – 1.9 
1.2 – 1.81 
1.04 – 1.78 
0 – 1.52 
 
 
1.40(0.34) 
1.59(0.26) 
1.63(0.25) 
1.33(0.44) 
1.03(0.45) 
 
 
0 – 1.7 
1 – 1.9 
1.08 – 1.95 
0 – 1.78 
0 – 1.52 
 
 
0.523 
0.355 
0.011 
0.567 
0.958 
With glare 
Spatial 
frequency 
      1.5 
      3 
      6  
      12 
      18 
 
 
1.33(0.20) 
1.52(0.21) 
1.50(0.21) 
1.24(0.39) 
0.95(0.33) 
 
 
0.95 – 1.7 
1 – 1.9 
1.08 – 1.81 
0 – 1.78 
0 – 1.52 
 
 
1.39(0.33) 
1.56(0.34) 
1.58(0.33) 
1.26(0.53) 
1.00(0.45) 
 
 
0 – 1.7 
0 – 1.9 
0 – 1.95 
0 – 1.78 
0 – 1.52 
 
 
0.210 
0.422 
0.079 
0.830 
0.493 
 
 
 
 
 
 
Contrast sensitivity assessment (Night) in both eyes 
 
Contrast 
sensitivity 
(Night) Both 
eyes 
Pre treatment Post treatment 
P-value Mean(SD) Min – Max Mean(SD) Min – Max 
Without glare 
Spatial 
frequency 
      1.5 
      3 
      6  
      12 
      18 
 
 
1.27(0.21) 
1.60(0.77) 
1.33(0.47) 
1.08(0.51) 
0.86(0.43) 
 
 
0.85 – 1.56 
1 – 4.6 
0 – 1.81 
0 – 1.63 
0 – 1.36 
 
 
1.26(0.47) 
1.35(0.60) 
1.40(0.61) 
1.22(0.55) 
1.00(0.39) 
 
 
0 – 1.7 
0 – 1.9 
0 – 1.95 
0 – 1.78 
0 – 1.52 
 
 
0.838 
0.055 
0.323 
0.087 
0.011 
With glare 
Spatial 
frequency 
      1.5 
      3 
      6  
      12 
      18 
 
 
1.13(0.45) 
1.35(0.97) 
1.13(0.63) 
0.89(0.58) 
0.66(0.48) 
 
 
0 – 1.56 
0 – 4.6 
0 – 1.81 
0 – 1.63 
0 – 1.36 
 
 
1.16(0.54) 
1.28(0.58) 
1.29(0.59) 
1.07(0.51) 
0.79(0.46) 
 
 
0 – 1.7 
0 – 1.9 
0 – 1.95 
0 – 1.78 
0 – 1.52 
 
 
0.667 
0.625 
0.032 
0.006 
0.055 
 
 
 
 
 
 
 
Contrast sensitivity assessment in affected eyes based on Anatomical 
location 
 
CS 
Location 
Anterior Intermediate Posterior Pan 
Pre 
treatment 
Post 
treatmen
t 
Pre 
treatment 
Post 
treatment 
Pre 
treatment 
Post 
treatment 
Pre 
treatment 
Post 
treatment 
Day 
WOG 
      1.5 
      3 
      6 
      12 
      18 
 
5(21.7) 
2(8.7) 
3(13.0) 
14(60.9) 
14(60.9) 
 
20(87.0) 
20(87.0) 
18(78.3) 
20(87.0) 
20(87.0) 
 
6(35.3) 
6(35.3) 
6(35.3) 
14(82.4) 
14(82.4) 
 
12(70.6) 
12(70.6) 
10(58.8) 
16(94.1) 
16(94.1) 
 
2(16.7) 
3(25.0) 
2(16.7) 
8(66.7) 
8(66.7) 
 
5(41.7) 
5(41.7) 
5(41.7) 
5(41.7) 
9(75.0) 
 
- 
- 
- 
2(7.1) 
14(50.0) 
 
4(14.3) 
4(14.3) 
- 
12(42.9) 
12(42.9) 
Day WG 
      1.5 
      3 
      6 
      12 
      18 
 
5(21.7) 
- 
- 
10(43.5) 
14(60.9) 
 
16(69.6) 
13(56.5) 
13(56.5) 
20(87.0) 
20(87.0) 
 
2(11.8) 
2(11.8) 
2(11.8) 
10(58.8) 
10(58.8) 
 
12(70.6) 
12(70.6) 
6(35.3) 
16(94.1) 
16(94.1) 
 
2(16.7) 
2(16.7) 
2(16.7) 
7(58.3) 
7(58.3) 
 
5(41.7) 
5(41.7) 
5(41.7) 
5(41.7) 
9(75.0) 
 
- 
- 
- 
2(7.1) 
10(35.7) 
 
2(7.1) 
2(7.1) 
 
6(21.4) 
12(42.9) 
Night 
WOG 
      1.5 
      3 
      6 
      12 
      18 
 
3(13.0) 
- 
- 
11(47.8) 
14(60.9) 
 
17(73.9) 
14(60.9) 
9(39.1) 
20(87.0) 
20(87.0) 
 
- 
- 
2(11.8) 
8(47.1) 
12(70.6) 
 
8(47.1) 
6(35.3) 
6(35.3) 
16(94.1) 
16(94.1) 
 
1(8.3) 
1(8.3) 
1(8.3) 
5(41.7) 
5(41.7) 
 
3(25.0) 
2(16.7) 
2(16.7) 
5(41.7) 
9(75.0) 
 
- 
- 
- 
- 
- 
 
- 
- 
- 
10(35.7) 
10(35.7) 
Night 
WG 
      1.5 
      3 
      6 
      12 
      18 
 
3(13.0) 
- 
- 
8(34.8) 
10(43.5) 
 
9(39.1) 
7(30.4) 
7(30.4) 
19(82.6) 
19(82.6) 
 
- 
- 
2(11.8) 
8(47.1) 
8(47.1) 
 
4(23.5) 
4(23.5) 
2(11.8) 
6(35.3) 
12(70.6) 
 
1(8.3) 
1(8.3) 
1(8.3) 
1(8.3) 
4(33.3) 
 
3(25.0) 
1(8.3) 
1(8.3) 
5(41.7) 
5(41.7) 
 
- 
- 
- 
- 
- 
 
- 
- 
- 
2(7.1) 
2(7.1) 
 
 
 
 
 
 
 
 
Contrast sensitivity assessment in both eyes based on Anatomical 
location 
 
CS 
Location 
Anterior Intermediate Posterior Pan 
Pre 
treatment 
Post 
treatment 
Pre 
treatmen
t 
Post 
treatment 
Pre 
treatment 
Post 
treatment 
Pre 
treatment 
Post 
treatment 
Both eyes (n=54) 
Day 
WOG 
      1.5 
      3 
      6 
      12 
      18 
 
5(35.7) 
5(35.7) 
1(7.1) 
12(85.7) 
12(85.7) 
 
13(92.9) 
13(92.9) 
11(78.6) 
14(100.0) 
14(100.0) 
 
3(37.5) 
3(37.5) 
3(37.5) 
7(87.5) 
7(87.5) 
 
6(75.0) 
6(75.0) 
6(75.0) 
8(100.0) 
8(100.0) 
 
5(83.3) 
4(66.7) 
3(50.0) 
6(100.0) 
6(100.0) 
 
2(33.3) 
1(16.7) 
1(16.7) 
4(66.7) 
6(100.0) 
 
- 
- 
- 
1(7.1) 
7(50.0) 
 
2(14.3) 
2(14.3) 
- 
3(21.4) 
4(28.6) 
Day 
WG 
      1.5 
      3 
      6 
      12 
      18 
 
5(35.7) 
3(21.4) 
- 
12(85.7) 
12(85.7) 
 
13(92.9) 
13(92.9) 
10(71.4) 
13(92.9) 
14(100.0) 
 
1(12.5) 
1(12.5) 
1(12.5) 
5(62.5) 
5(62.5) 
 
6(75.0) 
6(75.0) 
3(37.5) 
8(100.0) 
8(100.0) 
 
5(83.3) 
4(66.7) 
3(50.0) 
6(100.0) 
6(100.0) 
 
2(33.3) 
1(16.7) 
1(16.7) 
3(50.0) 
6(100.0) 
 
- 
- 
- 
1(7.1) 
5(35.7) 
 
1(7.1) 
1(7.1) 
- 
2(14.3) 
5(35.7) 
Night 
WOG 
      1.5 
      3 
      6 
      12 
      18 
 
4(28.6) 
1(7.1) 
- 
9(64.3) 
14(100.0) 
 
13(92.9) 
11(78.6) 
10(71.4) 
13(92.9) 
14(100.0) 
 
1(12.5) 
1(12.5) 
1(12.5) 
5(62.5) 
7(87.5) 
 
4(50.0) 
4(50.0) 
3(37.5) 
8(100.0) 
8(100.0) 
 
1(16.7) 
3(50.0) 
1(16.7) 
4(66.7) 
6(100.0) 
 
1(16.7) 
2(33.3) 
2(33.3) 
2(33.3) 
5(83.3) 
 
- 
- 
- 
- 
- 
 
- 
- 
- 
5(35.7) 
5(35.7) 
Night 
WG 
      1.5 
      3 
      6 
      12 
      18 
 
3(21.4) 
- 
- 
5(35.7) 
8(57.1) 
 
10(71.4) 
6(42.9) 
4(28.6) 
11(78.6) 
13(92.9) 
 
1(12.5) 
1(12.5) 
1(12.5) 
5(62.5) 
5(62.5) 
 
3(37.5) 
3(37.5) 
1(12.5) 
3(37.5) 
6(75.0) 
 
1(16.7) 
3(50.0) 
1(16.7) 
3(50.0) 
4(66.7) 
 
1(16.7) 
1(16.7) 
1(16.7) 
1(16.7) 
2(33.3) 
 
- 
- 
- 
- 
- 
 
- 
- 
- 
1(7.1) 
1(7.1) 
 
 
 
 
 
 
 
 
 
Overall assessment of Contrast sensitivity 
CS 
Eye 
Affected eye Unaffected eye Both eye 
Mean(SD) Min – Max  
Mean 
(SD) 
Min – Max  
Mean 
(SD) 
Min – Max  
Day WOG 
      1.5 
      3 
      6 
      12 
      18 
 
1.29(0.16) 
1.46(0.20) 
1.47(0.21) 
1.29(0.21) 
0.94(0.36) 
 
1.11 – 1.70 
1.18 – 2.06 
1.20 – 2.11 
1.04 – 1.78 
0 – 1.52  
 
1.74(0.10) 
2.01(0.10) 
1.99(0.12) 
1.80(0.12) 
1.52(0.11) 
 
1.40 – 1.85 
1.60 – 2.06 
1.65 – 2.11  
1.48 – 1.93 
1.23 – 1.66 
 
1.37(0.17) 
1.56(0.19) 
1.55(0.19) 
1.37(0.18) 
1.02(0.31) 
 
1.11 – 1.70 
1.18 – 1.90 
1.20 – 1.81 
1.04 – 1.78 
0 – 1.52 
Day WG 
      1.5 
      3 
      6 
      12 
      18 
 
1.23(0.20) 
1.39(0.22) 
1.42(0.23) 
1.09(0.44) 
0.83(0.43) 
 
0.95 – 1.70 
1.00 – 2.06 
1.08 – 2.11 
0 – 1.78 
0 – 1.52 
 
1.74(0.10) 
2.01(0.10) 
1.99(0.13) 
1.81(0.12) 
1.52(0.11) 
 
1.40 – 1.85 
1.60 – 2.06 
1.65 – 2.11  
1.48 – 1.93 
1.23 – 1.66 
 
1.33(0.20) 
1.52(0.21) 
1.50(0.21) 
1.24(0.39) 
0.95(0.33) 
 
0.95 – 1.70 
1.00 – 1.90 
1.08 – 1.81  
0 – 1.78 
0 – 1.52 
Night WOG 
      1.5 
      3 
      6 
      12 
      18 
 
1.12(0.30) 
1.25(0.33) 
1.18(0.49) 
0.81(0.60) 
0.64(0.49) 
 
0 – 1.7 
0 – 2.06 
0 – 2.11 
0 – 1.78 
0 – 1.52 
 
1.74(0.12) 
2.00(0.13) 
1.99(0.14) 
1.80(0.14) 
1.52(0.13) 
 
1.26 – 1.85 
1.46 – 2.06 
1.52 – 2.11 
1.34 – 1.93 
1.08 – 1.66 
 
1.27(0.21) 
1.60(0.77) 
1.33(0.47) 
1.08(0.51) 
0.86(0.42) 
 
0.85 – 1.56 
1 – 4.6 
0 – 1.81 
0 – 1.63 
0 – 1.36 
Night WG 
      1.5 
      3 
      6 
      12 
      18 
 
0.98(0.43) 
1.00(0.52) 
0.85(0.67) 
0.51(0.63) 
0.38(0.51) 
 
0 – 1.7 
0 – 2.06 
0 – 2.11 
0 – 1.78 
0 – 1.52 
 
1.74(0.12) 
2.00(0.15) 
1.98(0.16) 
1.77(0.17) 
1.49(0.16) 
 
1.26 – 1.85 
1.30 – 2.06 
1.36 – 2.11 
1.18 – 1.93 
0.90 – 1.66 
 
1.13(0.45) 
1.35(0.97) 
1.13(0.63) 
0.89(0.58) 
0.66(0.48) 
 
0– 1.56 
0 – 4.60 
0 – 1.81 
0 – 1.63 
0 – 1.36 
 
 
 
Quality of life in Anterior Uveitis
 
Quality of life in Intermediate Uveitis
22.29
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3.86
1.50
14.21
4.43
Post treatment
Anterior Uveitis
Psychosocial impact Visual symptoms
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Psychosocial impact Visual symptoms
 
 
 
 
 
Quality of life in Posterior Uveitis
 
Quality of life in Pan 
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Uveitis 
36.00
9.83
15.83 16.33
Post treatment
Posterior Uveitis
General functioning Psychosocial impact
45.71
10.64
18.93 17.00
Post treatment
Pan Uveitis
Psychosocial impact Visual symptoms
 
 
 
 
 
 
Quality of life is assessed for individual types of uveitis based on anatomical 
location .it is assessed for three different types of scale such as general 
functioning,Psychosocial impact and visual symptoms. 
The assessment showed that patient with anterior uveitis showed better 
improvement in quality of life post treatment. 
Intermediate uveitis also showed  improvement in quality of life post 
treatment. 
Quality of life is drastically affected in patient with posterior and Panuveitis. 
Overall assessment showed that quality of life improved in patients with 
uveitis post treatment.it shows that treatment has effect on quality of life. So, 
the patient should be adequately treated not only to reduce the progression of 
disease but also to relieve the  stress, visual disability and its impact on day to 
day life. 
 
 
 
 
 
 
 
 
 
 
 
 
Quality of life assessment based on Anatomical location 
Anatomical 
location 
Quality of life assessment 
P-value Pre treatment Post treatment Mean(SD) Min – 
Max 
Mean(SD) Min – 
Max 
Anterior uveitis 
    General 
functioning 
    Psychosocial 
impact  
    Visual 
symptoms 
 
22.29(11.18) 
 
8.14(3.35) 
 
14.21(2.64) 
 
8 – 41  
 
4 – 15  
 
11 – 20  
 
3.86(9.99) 
 
1.50(3.67) 
 
4.43(5.63) 
 
0 – 38  
 
0 – 14  
 
0 – 21  
 
0.0014 
 
0.0014 
 
0.0024 
Intermediate 
uveitis 
      General 
functioning 
    Psychosocial 
impact  
    Visual 
symptoms 
 
 
31.00(12.54) 
 
10.50(3.78) 
 
17.38(3.89) 
 
 
15 – 44  
 
6 – 14  
 
13 – 21  
 
 
8.63(8.55) 
 
3.38(2.62) 
 
6.75(4.92) 
 
 
0 – 21  
 
0 – 6  
 
0 – 13  
 
 
0.011 
 
0.011 
 
0.011 
Posterior uveitis 
     General 
functioning 
    Psychosocial 
impact  
    Visual 
symptoms 
 
30.17(6.65) 
 
10.00(2.28) 
 
15.83(2.99) 
 
22 – 42  
 
7 – 14  
 
14 – 21  
 
36.00(30.56) 
 
9.83(5.88) 
 
16.33(5.71) 
 
0 – 63  
 
2 – 15  
 
7 – 21  
 
0.599 
 
0.999 
 
0.739 
Pan uveitis 
    General 
functioning 
    Psychosocial 
impact  
    Visual 
symptoms 
 
48.00(10.57) 
 
12.86(2.28) 
 
18.93(3.25) 
 
30 – 63  
 
10 – 15  
 
14 – 21  
 
45.71(24.71) 
 
10.64(5.34) 
 
17.00(5.29) 
 
8 – 84  
 
3 – 15  
 
7 – 21  
 
0.612 
 
0.216 
 
0.379 
Total  
    General 
functioning 
    Psychosocial 
impact  
    Visual 
symptoms 
 
31.78(14.45) 
 
10.31(3.58) 
 
16.35(3.98) 
 
1 – 63 
 
1 – 15 
 
4 – 21 
 
22.20(25.27) 
 
6.13(5.88) 
 
10.98(7.67) 
 
0 – 84 
 
0 - 15 
 
0 – 21 
 
0.0014 
 
<0.001 
 
0.0001 
 
 
 
 
 
Correlation between Visual acuity,Contrast sensitivity and Quality of life 
 
Variable Correlation 
coefficient 
P-value 
CS Day WOG with 
QOL 
-0.88 <0.001 
CS Day WG with 
QOL 
-0.85 <0.001 
CS Night WOG with 
QOL 
-0.85 <0.001 
CS Night WG with 
QOL 
-0.88 <0.001 
BCVA with QOL 0.78 <0.001 
BCVA with CS -0.91 <0.001 
 
 
There is a close correlation between the visual acuity and Contrast Sensitivity 
and also there is a high correlation between the visual acuity and Quality of 
life. 
There is a negative correlation (but significant) between the Quality of life 
and Contrast Sensitivity of Day and Night time under conditions of without 
glare and with glare 
 
 
 
 
 
 
 
 
Correlation between Contrast sensitivity(Day) with out glare and QOL 
 
 
Correlation between Contrast sensitivity(Day) with  glare and QOL 
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Correlation between Contrast sensitivity(Night) with out glare and QOL 
 
 
Correlation between Contrast sensitivity(Night) with  glare and QOL 
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Correlation between Visual acuity and QOL 
 
 
Corelation between Visual acuity and Contrast sensitivity 
 
0
50
10
0
15
0
To
ta
l Q
O
L 
sc
or
e
0 .2 .4 .6 .8 1
LogMAR BCVA at 1month
.5
1
1.
5
2
C
on
tra
st
 S
en
si
tiv
ity
0 .2 .4 .6 .8 1
LogMAR BCVA at 1month
 
 
 
 
DISCUSSION 
Uveitis are vision threatening condition which may cause distress and 
disability in life,hence it is one of the cause for preventable and economic 
blindnes .It has a heterogenous group of different anatomical,pathological 
and etiological entities. 
Generally in Ophthalmology,visual acuity is the only measure used to 
test visual function but it inadequately measure the visual performance,which 
may be affected by other measures which includes contrast sensitivity,colour 
vision,visual field examination and stereopsis. 
It is that contrast sensitivity is a strong indicator of visual function. 
Contrast sensitivity testing determines the association between optical clarity 
and the minimum retinal threshold for particular pattern of the object. 
Therefore contrast sensitivity strongly denotes functional vision as a 
whole.Vision is most important  of all senses.It is most  of the information 
from the external  world is appreciated through the visual system. 
In Ophthalmology, the Quality of life and visual functions has been 
assessed with visual function assessment questionnaires for many diseases 
like Cataract,Age related macular degeneration,Glaucoma,Low vision 
patients etc.,.But still less studies were conducted in uveitis,and hence it was 
decided to analyse “ visual function and the quality of life in Uveitic 
Patients” and to verify the effect of treatment in the same population and to 
 
 
 
 
correlate with the contrast sensitivity in day and night vision with and 
without glare. 
Hence,it will assess the patients subjective feeling of the disease 
process than the clinicial findings assessed by the doctors. 
It is the first of its kind of study to assess contrast sensitivity in uveitis 
patients in day and night situations under the conditions of without glare and 
glare. 
In this study 54 patients were enrolled. 
No eligible patients were refused. 
No selection citeria other than inclusion/exclusion criteria were used. 
All the patients were advised to come for review after one month. 
All the patients were adequately treated according to the condition 
All the assessment was mainly based on the anatomical location of the uveitis 
as Anterior uveitis,Intermediate Uveitis,Posterior uveitis and Pan uveitis. 
The demographic values,clinical parameters,visual function values and 
different scales of quality of life were assessed pre and post treatment. 
The normal eyes were also assessed for visual acuity and contrast sensivity.it 
is done to compare values with affected eyes and also assess the binocular 
values and its effect on different scales of visual function questionnaire 
 
 
 
 
 
 
 
Demographic values: 
In this study, a total of 54 patients were included. 
Regarding demographic values,Mean age of presentation of disease was 32 
years with the range between 16 and 48 years. 
Males and  females were almost equally affected. 
Right eye was most commonly involved than left eye. 
It was unilaterally  involved in 51.8% patients and bilateral in 48.2% patients. 
Among 108 eyes of 54 patients,pan uveitis was most commonly affected 
followed by anterior,intermediate and posterior uveitis. 
Most of the patient received topical corticosteroids followed by systemic 
corticosteroids,combined topical and systemic corticosteroids,anti-microbials 
and immunosuppressants. 
 
Effect on visual acuity: 
The patient affected with anterior uveitis(P value-0.0051) and 
Intermediate uveitis (P value 0.0002) showed significant improvement in 
visual acuity post treatment.there is no significant improvement in visual 
acuity in patients with Posterior uveitis(P value-0.11) post treatment.visual 
acuity is mostly reduced in Pan uveitis.There is no significant improvement 
(P value-0.5833) in visual acuity in patient with pan uveitis. 
 
 
 
 
Overall the patients with uveitis showed significant improvement in 
visual acity post treatment(P value-0.0001).This shows that treatment has 
effect on visual acuity improvement.so,all patients with different types of 
uveitis should be adequately treated according to the course. 
 
Effect on Contrast sensitivity: 
Assessment in affected eyes: 
Day time with out glare: 
The overall assessment of contrast sensitivity in day time situations 
with out glare with log contrast values  showed that there is significant 
improvement in spatial frequencies of 1.5,3,6 cpd  post treatment but there is 
no significant improvement in contrast sensitivity at higher spatial 
frequencies such as 12 and 18 cpd 
 
Day time with glare: 
The overall assessment of contrast sensitivity in day time situations 
with glare with log contrast values  showed that there is no significant 
improvement in contrast sensitivity at all spatial frequencies. 
In this condition contrast sensitivity at higher spatial frequencies such as 12 
and 18 are highly affected. 
 
 
 
 
 
 
Night time with out glare: 
The overall assessment of contrast sensitivity in night time situations 
without glare with log contrast values showed that contrast sensitivity is 
highly affected at 1.5,3,and 6 cpd spatial frequencies but less affected at 
higher spatial frequencies(12 and 18 cpd) 
 
Night time with glare: 
The overall assessment of contrast sensitivity in night time situations 
without glare with log contrast values showed that contrast sensitivity is 
highly affected at1.5 and 3 cpd spatial frequencies but less affected at 6,12 
and 18 cpd spatial frequencies. 
So,contrast sensitivity in affected eyes showed that it is reduced in day 
light with glare  and night with and without glare in 1.5,3 and 6 cpd spatial 
frequencies. Higher spatial frequencies such as 12 and 18 cpd are least 
affected in night situations. 
Overall contrast sensitivity is reduced in patients with uveitis but 
gradually improves with treatment. 
 
Contrast sensitivity in both eyes: 
The binocular assessment of  contrast sensitivity showed that contrast 
sensitivity is reduced in all conditions such as day and night time with and 
without glare. 
 
 
 
 
There is no significant improvement in contrast sensitivity post 
treatment. 
It shows that uveitis affects contrast sensitivity in patients.inspite of 
adequate treatment ,binocular contrast sensitivity is reduced in compare with 
contrast sensitivity assessment with affected eyes. 
 
Based on Anatomical location of Uveitis:  
Contrast sensitivity assessed on the basis of anatomical location of uveitis 
showed that contrast sensitivity in all spatial frequencies in both day and light 
situations with and without glare showed improvement post treatment in both 
Anterior and Intermediate uveitis. 
In posterior uveitis,contrast sensitivity is slightly improved in day time 
conditions with and with out glare but no significant improvement in night 
situations. 
Contrast sensitivity is drastically affected in patients with Panuveitis in 
all situations in comparision to other uveitis. 
 
Contrast sensitivity in comparison with normal eyes: 
Contrast assessed in affected eyes is compared with normal eyes 
showed that contrast sensitivity is reduced from normal values in patients 
with uveitis. 
 
 
 
 
 
Quality of life assessment : 
Bases on Anatomical location of uveitis: 
Quality of life is assessed for individual types of uveitis based on 
anatomical location .It is assessed for three different types of scale such as 
general functioning,Psychosocial impact and visual symptoms. 
The assessment showed that patient with anterior uveitis showed better 
improvement in quality of life post treatment. 
Intermediate uveitis also showed improvement in quality of life post 
treatment. 
Quality of life is drastically affected in patient with posterior and 
Panuveitis. 
Overall assessment showed that quality of life improved in patients with 
uveitis post treatment.It shows that treatment has effect on quality of 
life.So,the patient should be adequately treated not only to reduce the 
progression of disease but also to relieve the  stress,visual diability and its 
impact on day to day life. 
 
Correlation of visual function with quality of life: 
The correlation of visual function such as visual acuity and contrast 
sensitivity in day and night situations with and without glare with quality of 
life assessment showed that there is a high correlation with visual acuity and 
contrast sensitivity.(p<0.001) ,high correlation with visual acuity and quality 
 
 
 
 
of life(p<0.001).There  is also high correlation of quality of life with contrast 
sensitivity in day and night situations with and without glare.(p<0.001) 
Hence,both visual acuity a and contrast sensivity can be used to assess 
the quality of life but visual acuity by snellen’s will measure only at high 
contrast.Contrast sensitivity with FACT under day and light conditions with 
and without glare is used to assess the patient subjective observation in real 
life situations. 
Patients with complications such as cataract,cystoid macular 
edema,epiretinal membrane and others drastically affected the visual function 
and quality of life. 
It is the first of its kind that this study is conducted.There is no basic 
comparision for this study. 
But visual function and quality of life has assessed in uveitis in general ,in 
intermediate uveitis,Juvenile rheumatoid arthritis associated uveitis and 
toxoplasmosis. 
Each study used different parameters and different parameters and 
questionnaire to assess the visual function and quality of life 
Granier et al75concluded that Binocular contrast sensitivity is the best 
measure to measure the visual function in uveitis patients  in real 
situations.the young patients with poor binocular visual acuity had worst 
quality of life. 
 
 
 
 
In contrast to this study our study showed that Both visual acuity and contrast 
sensitivity can be used to assess quality of life in uveitis patients. 
 
Rhelt M et al72 revealed that uveitis affects the visual functioning and 
general health of the patients.More severe the disease more pronounced is the 
fall in visual functioning scores. 
Our study also showed the similar results that uveitis affects the visual 
function and quality of life at presentation but improves after treatment 
 
C C Murphy et al76 concluded that majority of patients with Intermediate 
Uveitis maintain good visual function and quality of life.Impaired VR-QOL 
and HR-QOL correlates with worse eye with Intermediate Uveitis 
In our study,visual acuity and quality of life improved after treatment but 
there is  no significant improvement in contrast sensitivity post treatment. 
 
Janine Scherrer et al78 in their study in ocular toxoplasmosis showed that 
Standard automated perimetry may better reflect the functional damage than 
visual acuity” 
In our study,visual field is not analysed. 
 
 
 
 
 
 
Aravind Venkatraman et al79 showed that visual function  scores improved 
significantly in patients with uveitis post treatment and there is a correlation 
to visual acuity thus illustrates  that VR-QOL is effective in assessing the 
effectiveness of treatment. 
Our study showed that there is a strong correlation between visual acuity, 
contrast sensitivity  and quality of life.both visual function and quality of life 
improves with treatment. 
 
 
  
 
 
 
 
CONCLUSION 
It is concluded that  
The patients with uveitis showed significant improvement in visual acuity 
post treatment.This shows that treatment has effect on visual acuity 
improvement.hence,all patients with different types of uveitis should be 
adequately treated according to the course. 
          Contrast sensitivity is drastically reduced in patients with Panuveitis  
and also in posterior uveitis.Anterior and Intermediate uveitis showed better 
improvement in contrast sensitivity post treatment. Overall Contrast 
sensitivity is reduced in patients with uveitis but gradually improves with 
treatment 
Patient with Anterior uveitis showed better improvement in quality of 
life post treatment. Intermediate uveitis also showed improvement in quality 
of life post treatment. Quality of life is drastically affected in patient with 
posterior and Panuveitis 
There is high correlation between visual acuity with contrast sensitivity in 
day and night situations with and with out glare and then with quality of life 
Hence, both Visual acuity and Contrast sensitivity can be used to assess the 
Quality of life but contrast sensitivity will show subject observation in real 
time situations. 
 
 
 
 
 
LIMITATIONS 
The limitations of this study are 
 
Ø It is not done in pediatric population since questionnaire was 
designed for adult population. 
 
Ø Patient with poor visual acuity i.e., who are not able to read letters 
in snellen chart are not included for the ease of stastical analysis. 
 
 
Ø The study can be extended by longterm follow up to understand the 
real visual sequalae 
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PROFORMA 
( Key to Master chart ) 
 
Name  : 
Age   :     Sex : 
MR.NO: 
Mobile No  : 
Address  : 
 
Study Eye  : RE-1;  LE-2;  BE-3 
Anatomical location:    RIGHT   LEFT
     Anterior-1 
Intermediate-2 
Posterior-3 
Panuveitis-4 
Pre-Treatment Assessment:  RIGHT   LEFT  
BCVA 
NCT 
Anterior Segment findings:  RIGHT   LEFT 
Scleritis  
Absent-0:  Present-1 
 
 
 
 
 
 
 
 
Keratic precipitates            RIGHT                  LEFT   
Absent-0;present-1 
AC Cells(0,1+,2+,3+,4+) 
AC Flare (0,1+,2+,3+,4+) 
Synechiae 
Absent-0:Present-1   
Hypopyon 
Absent-0:Present-1 
Lens status 
Clear-1;lens changes-2; 
Cataract-3;Pseudophakia-4; 
Aphakia-5 
Posterior segment findings: 
Media 
clear-1;Hazy-2 
Vitreous cells 
Absent-0;Present-1 
Vitreous opacities  
Absent-0;Present-1 
Pars planitis  
Bank-1;balls-2;both-3 
Vasculitis 
Absent-0;Present-1 
Retinitis              
 
 
 
 
  RIGHT                  LEFT       
Absent-0:Focal-1;multifocal-2 
Retinochoriditis 
Absent-0:Focal-1;multifocal-2 
Papillitis 
Absent-0;Present-1 
Vitreous Hemorrhage 
Absent-0;Present-1 
CME 
Absent-0;Present-1 
ERM 
Absent-0;Present-1 
CNVM 
Absent-0;Present-1 
Optic atrophy 
Absent-0;Present-1  
Treatment:   
0-no treatment; 
1-Topical corticosteroids, 
2-systemic Corticosteroids, 
3-Cycloplegics; 
4-immunosuppresants, 
5-others like Anti-microbials  
6-Periocular steroid 
 
 
 
 
Contrast Sensitivity Assessment: 
Recorded in FACT recording form 
The values are recorded as log contrast values 
(Recording form,Log contrast values attached) 
 
Quality of Life Assessment: 
Recorded in IND VFQ-33 form 
(IND VFQ-33 questionnaire attached) 
 
It has three scales 
1.General functioning questions(question 1 to 21) 
2.Psychosocial questions(question 22 to 26) 
3.visual symptoms questions(question 27 to 33) 
 
The response is recorded as follows: 
For General functioning scale: 
0-Not at all 
1-A little 
2-Quite a bit 
3-A lot 
4-Cannot do this because of my sight 
 
 
 
 
 
 
For Psychosocial impact and Visual symptoms scale: 
0-Not at all 
1-A little 
2-Quite a bit 
3-A lot 
 
Post-treatment Assessment(1 month follow up) 
Assesed same as in Pre-treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Indian Visual Function Questionnaire (IND – VFQ 33)  
Patient Name: ________________________________________________ Age : _______ Sex : M / F 
M.R.No: _________________________     Interview’s Name : __________________________ 
In first section, I am going to ask you how much your vision problem affects you in doing your daily 
activities. I will read out a choice of four answers and you will choose the one you feel describes you 
best. If you cannot do or don't do this activity because of vision or other reasons, please tell me 
S.No Questions Not at all 
A 
little 
Quite 
a bit 
A 
lot 
Cannot do 
this 
because of 
my sight 
1 
Because of your vision how much 
problem do you have in climbing 
stairs?           
2. 
Because of your vision how much 
problem do you have in making out 
the bumps and holes in the road when 
walking?      
3. 
Because of your vision how much 
problem do you have in seeing if there 
are animals or vehicles when 
walking?      
4. 
Because of your vision how much 
problem do you have in finding your 
way in new places?      
5. 
Because of your vision how much 
problem do you have in going to 
social functions such as weddings?      
6. 
Because of your vision how much 
problem do you have in going out at 
night?      
7. 
Because of your vision how much 
problem do you have in finding your 
way indoors?      
8. 
Because of your vision how much 
problem do you have in seeing the 
steps of the bus when climbing in or 
out?      
9. 
Because of your vision how much 
problem do you have in recognising 
people from a distance?      
10. 
Because of your vision how much 
problem do you have in recognising 
the face of a person standing near 
you?      
 
 
 
 
 
 
 
 
 
 
S.No Questions Not at all 
A 
little 
Quite 
a bit 
A 
lot 
Cannot do 
this 
because of 
my sight 
11. 
Because of your vision how much 
problem do you have in locking or 
unlocking the door?      
12 
Because of your vision how much pro 
blem do you have in doing your usual 
work either in the house or outside?      
13 
Because of your vision how much 
problem do you have in doing your 
work up to your usual standard?      
14 
Because of your vision how much 
problem do you have in searching for 
things at home?      
15 
Because of your vision how much 
problem do you have in seeing outside 
in bright sunlight      
16 
Because of your vision how much 
problem do you have in seeing when 
coming into the house after being in 
the sunlight?      
17 
Because of your vision how much 
problem do you have in seeing 
differences in colours?      
18 
Because of your vision how much 
problem do you have in making out 
differences in coins or notes?      
19 
Because of your vision how much 
problem do you have in going to the 
toilet?      
20 
Because of your vision how much 
problem do you have in seeing objects 
that may have fallen in the food?      
21 
Because of your vision how much 
problem do you have in seeing the 
level in the container when pouring?       
 
 
 
 
 
 
 
 
 
 
Signature of interviewer  
 
Date : 
Place : 
  
In  the next section ,I am going to ask you how you feel because of your eye problem ,I will red out a 
choice of four answers and you will choose the one you feel describes you best 
S.No Questions Not at all 
A 
little 
Quite 
a bit A lot 
22 
Because of your eye problem do you feel frightened 
to go out at night?     
23 
Because of your eye problem do you enjoy social 
functions less?     
24 
Because of your eye problem do you ashamed that 
you can’t see?     
25 
Because of your eye problem do you feel you have 
become a burden on others?     
26 
Because of your eye problem do you feel frightened 
that you may lose your remaining vision?     
In the next section, I am going to ask you to what extent do you have the following eye problems. I 
will read out a choice off our answers and you will choose the one you feel describes you best. 
S.No Questions Not at all 
A 
little 
Quite 
a bit A lot 
27 Do you have reduced vision?     
28 Are you dazzled in bright light?     
29 Is your vision blurred in sunlight?     
30 Does bright light hurt your eyes?     
31 
Do you close your eyes because of light from 
vehicles?     
32 Does light seem like stars?     
33 Do you have blurred vision?     
 
 
 
 
ABBREVIATIONS 
VA  - Visual Acuity 
BCVA - Best Corrected Visual Acuity 
CS  - Contrast Sensitivity 
Log MAR - Logarithmic Minimum Angle Resolution 
Log CS - Logarithmic Contrast Sensitivity 
FACT - Functional Acuity Contrast Test 
cpd  - cycles per degree 
WOG  - With out Glare 
WG  - With Glare 
QOL  - Quality Of Life 
VR-QOL - Vision Related Quality Of Life 
IND-VFQ33 - Indian Visual Function Questionnaire 33 
SUN  - Standardisation of Uveitis Nomenclature 
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Anterior Segment Posterior Segment
Contrast Sensitivity
1.
5 3 6 12 18 1.
5 3 6 12 18
1 3760340 Nixon 25 M 1 1 6  12 1 4 0 1 3+ 2+ 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.11 1.3 1.36 1.04 0.6 0.95 1.18 1.2 0.9 0
2 0 6 6 1 6 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.78 1.36 1.7 1.9 1.95 1.78 1.36
3 0 1.56 1.76 1.65 1.48 1.23 1.56 1.6 1.52 1.48 1.08
2 3866707 Kalailingam 27 M 1 2 6 12 1 2 0 0 0 0 0 0 1 2 1 0 1 0 0 0 0 0 0 0 0 0 1,2 1.26 1.3 1.36 1.18 0.78 1.11 1.3 1.2 1.04 0.78
2 2 6 12 1 4 0 0 0 0 0 0 1 2 1 0 1 0 0 0 0 0 0 0 0 0 1,2 1.26 1.3 1.36 1.18 0.78 1.11 1.3 1.2 1.04 0.78
3 1.26 1.3 1.36 1.18 0.78 1.11 1.3 1.2 1.04 0.78
3 3858600 Navaneethamma 30 F 1 0 6 6 1 8 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52
2 3 6 9 1 6 0 0 0 0 0 0 1 1 1 0 0 1 1 0 0 0 0 0 0 0 1,2,5 1.4 1.76 1.65 1.48 1.08 1.26 1.46 1.52 1.34 0.9
3 1.56 1.76 1.65 1.63 1.23 1.4 1.6 1.65 1.48 1.08
4 3858702 Amsavalli 35 F 1 4 6 18 1 9 0 1 3+ 2+ 1 0 1 2 1 1 0 0 2 0 0 0 0 0 0 0 1,2,3 1.11 1.3 1.36 1.18 0.9 0.95 1.18 1.2 1.04 0.78
2 4 6 12 1 7 0 1 2+ 2+ 1 0 1 2 1 1 0 0 2 0 0 0 0 0 0 0 1,2,3 1.26 1.3 1.36 1.18 0.9 0.95 1.18 1.2 1.04 0.78
3 1.26 1.3 1.36 1.18 0.9 1.11 1.18 1.08 0 0
5 3770085 Satish kumar 22 M 1 0 6 6 1 2 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.63 1.52 1.7 1.9 1.81 1.78 1.52
2 1 6 9 1 4 0 1 2+ 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.4 1.6 1.81 1.48 1.08 1.4 1.46 1.36 1.18 0.9
3 1.56 1.76 1.81 1.48 1.08 1.4 1.6 1.52 1.48 1.23
6 3769239 Kumar 32 M 1 1 6 24 1 7 0 1 4+ 2+ 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.26 1.3 1.2 1.04 0.78 1.11 1.3 1.2 0 0
2 0 6 6 1 6 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.52 1.85 2.06 2.11 1.93 1.52
3 1.4 1.6 1.65 1.34 1.08 1.4 1.6 1.52 1.34 0.9
7 3809947 Rejina mary 42 F 1 1 6 12 1 9 0 1 2+ 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.56 1.6 1.52 1.34 1.08 1.56 1.46 1.52 1.18 1.08
2 0 6 6 1 4 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.81 1.63 1.36 1.7 1.9 1.81 1.63 1.36
3 1.56 1.76 1.65 1.48 1.08 1.56 1.76 1.65 1.34 1.08
8 3860869 Suganthi 26 F 1 0 6 6 1 5 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52
2 3 6 24 1 6 0 0 0 0 0 0 1 2 1 0 0 0 2 2 0 0 0 0 0 0 1,5 1.11 1.18 1.2 1.04 0.6 1.11 1.18 1.2 0.9 0.6
3 1.26 1.6 1.36 1.34 0.9 1.26 1.6 1.36 1.34 0.9
9 3865605 Kalimuthu 22 M 1 4 6 24 1 9 0 0 3+ 2+ 0 1 1 2 1 0 0 1 1 0 0 0 0 0 0 0 1,2,3,4 1.11 1.3 1.36 1.18 0.78 1.11 1.3 1.36 1.18 0.78
2 4 6 36 1 4 0 1 3+ 2+ 0 1 1 2 1 0 0 1 1 0 0 0 0 0 0 0 1,2,3,4 1.11 1.3 1.36 1.18 0.78 1.11 1.3 1.36 1.18 0.78
3 1.11 1.3 1.36 1.18 0.78 1.11 1.3 1.36 1.18 0.78
10 3793782 Krishnaveni 45 F 1 2 6 12 1 2 0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.26 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.34 1.08
2 2 6 12 1 6 0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.26 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.34 1.08
3 1.26 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.34 1.08
11 3861683 Alagumeena 16 F 1 3 6 18 1 8 0 0 0 0 0 0 1 2 1 0 0 1 1 0 0 0 0 0 0 0 1,2,5 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.48 1.23
2 0 6 6 1 7 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52
3 1.56 1.6 1.65 1.48 1.08 1.56 1.6 1.65 1.48 1.08
12 3857077 Kannan 40 M 1 0 6 6 1 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52
2 1 6 24 1 6 0 1 3+ 2+ 0 0 1 2 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.26 1.46 1.36 1.04 0.78 1.26 1.46 1.36 1.04 0.78
3 1.4 1.6 1.65 1.34 1.23 1.4 1.6 1.65 1.34 1.08
13 3847038 Muthunayaki 45 F 1 4 6 36 1 8 0 1 3+ 2+ 0 0 1 2 1 1 1 0 0 2 0 0 0 0 0 0 1,2,3 1.11 1.18 1.2 1.04 0 0.95 1 1.08 0 0
2 4 6 24 1 4 0 1 3+ 2+ 0 0 1 2 1 1 1 0 0 2 0 0 0 0 0 0 1,2,3 1.11 1.18 1.2 1.04 0 0.95 1 1.08 0 0
3 1.11 1.18 1.2 1.04 0 0.95 1 1.08 0 0
14 3814160 Senthilnathan 32 M 1 2 6 12 2 0 0 0 0 0 0 0 1 2 1 0 1 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.81 1.63 1.36 1.56 1.76 1.81 1.63 1.36
2 0 6 6 1 8 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66
3 1.7 1.76 1.81 1.48 1.36 1.7 1.76 1.81 1.48 1.36
15 3860190 Parakath Nisha 32 F 1 1 6 9 1 7 0 1 2+ 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.34 1.23
2 1 6 9 1 2 0 1 2+ 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.34 1.23
3 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.34 1.23
16 3809870 Syed Ashraf Ali 42 M 1 1 6 9 1 4 0 0 3+ 1+ 0 0 4 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.56 1.6 1.52 1.34 1.08 1.56 1.46 1.52 1.18 1.08
2 0 6 6 1 2 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.81 1.63 1.36 1.7 1.9 1.81 1.63 1.36
3 1.56 1.76 1.65 1.48 1.08 1.56 1.76 1.65 1.34 1.08
17 3782079 Madhubharathi 48 F 1 2 6 18 1 6 0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.26 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.18 0.78
2 2 6 12 1 5 0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.26 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.18 0.78
3 1.26 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.18 0.78
18 3863517 Sivaiah 27 M 1 3 6 12 1 9 0 0 0 0 0 0 1 2 1 0 0 1 2 0 0 0 0 0 0 0 2,5 1.4 1.46 1.52 1.34 0.9 1.4 1.46 1.52 1.18 0.78
2 0 6 6 1 7 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66
3 1.56 1.76 1.65 1.48 1.08 1.56 1.76 1.65 1.48 1.08
19 3837544 Narayanan 41 M 1 4 6 18 1 2 0 0 3+ 2+ 0 0 1 2 1 1 1 1 2 0 0 0 0 0 0 0 1,2,3,4 1.26 1.46 1.36 1.18 0.9 1.11 1.3 1.36 1.18 0.9
2 4 6 18 1 6 0 0 3+ 2+ 0 0 1 2 1 1 1 1 2 0 0 0 0 0 0 0 1,2,3,4 1.26 1.46 1.36 1.18 0.9 1.11 1.3 1.36 1.18 0.9
3 1.26 1.46 1.36 1.18 0.9 1.11 1.3 1.36 1.18 0.9
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20 3855176 Ayyammal 27 F 1 1 6 12 1 7 0 1 3+ 2+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.48 1.23
2 1 6 12 1 5 1 3+ 2+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.48 1.23
3 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.48 1.23
21 3863131 Muthumari 28 F 1 0 6 6 1  2 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.52 1.85 2.06 2.11 1.93 1.52
2 1 6 24 1 5 0 1 4+ 2+ 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.26 1.3 1.2 1.04 0.78 1.11 1.3 1.2 0 0
3 1.4 1.6 1.65 1.34 1.08 1.4 1.6 1.52 1.34 0.9
22 3789300 Indhumathi 28 F 1 1 6 12 1 2 0 1 2+ 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.56 1.6 1.52 1.34 1.08 1.56 1.46 1.52 1.18 1.08
2 0 6 6 1 6 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.81 1.63 1.36 1.7 1.9 1.81 1.63 1.36
3 1.56 1.76 1.65 1.48 1.08 1.56 1.76 1.65 1.34 1.08
23 3838594 Muthiah 37 M 1 3 6 24 1 8 0 0 0 0 0 0 1 2 1 0 0 0 2 2 0 0 0 0 0 0 1,5 1.11 1.18 1.2 1.04 0.6 1.11 1.18 1.2 0.9 0.6
2 0 6 6 1 5 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52
3 1.26 1.6 1.36 1.34 0.9 1.26 1.6 1.36 1.34 0.9
24 3869997 Chellammal 45 F 1 4 6 36 1 7 1 1 3+ 2+ 0 0 1 2 1 1 1 0 0 2 0 0 0 0 0 0 1,2,3 1.11 1.18 1.2 1.04 0 0.95 1 1.08 0 0
2 4 6 24 1 6 1 1 3+ 2+ 0 0 1 2 1 1 1 0 0 2 0 0 0 0 0 0 1,2,3 1.11 1.18 1.2 1.04 0 0.95 1 1.08 0 0
3 1.11 1.18 1.2 1.04 0 0.95 1 1.08 0 0
25 3871440 Shanmugaraj 28 M 1 2 6 12 2 0 0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.26 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.34 1.08
2 2 6 12 1 7 0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.26 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.34 1.08
3 1.26 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.34 1.08
26 1474680 Suriya priya 18 F 1 0 6 6 1 2 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52
2 3 6 18 1 4 0 0 0 0 0 0 1 2 1 0 0 1 1 0 0 0 0 0 0 0 1,2,5 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.48 1.23
3 1.56 1.6 1.65 1.48 1.08 1.56 1.6 1.65 1.48 1.08
27 3863450 Sreenivasan 36 M 1 1 6 24 1 6 0 1 3+ 2+ 0 0 1 2 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.26 1.46 1.36 1.04 0.78 1.26 1.46 1.36 1.04 0.78
2 0 6 6 1 2 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52
3 1.4 1.6 1.65 1.34 1.23 1.4 1.6 1.65 1.34 1.08
28 2561490 Vettaisamy 38 M 1 4 6 24 2 0 0 0 3+ 2+ 0 1 1 2 1 0 0 1 1 0 0 0 0 0 0 0 1,2,3,4 1.11 1.3 1.36 1.18 0.78 1.11 1.3 1.36 1.18 0.78
2 4 6 36 1 8 0 1 3+ 2+ 0 1 1 2 1 0 0 1 1 0 0 0 0 0 0 0 1,2,3,4 1.11 1.3 1.36 1.18 0.78 1.11 1.3 1.36 1.18 0.78
3 1.11 1.3 1.36 1.18 0.78 1.11 1.3 1.36 1.18 0.78
29 3634225 Mercy 35 F 1 0 6 6 1 4 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66
2 2 6 12 1 7 0 0 0 0 0 0 1 2 1 0 1 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.81 1.63 1.36 1.56 1.76 1.81 1.63 1.36
3 1.7 1.76 1.81 1.48 1.36 1.7 1.76 1.81 1.48 1.36
30 3861038 Kalaivani 28 F 1 1 6 9 1 6 0 1 2+ 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.34 1.23
2 1 6 9 1 5 0 1 2+ 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.34 1.23
3 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.34 1.23
31 3837325 Mariyam 35 F 1 4 6 18 1 4 0 1 3+ 2+ 0 0 1 2 1 1 0 1 1 1 0 0 0 0 0 0 1,3,5 1.26 1.46 1.36 1.18 1.08 1.26 1.46 1.36 1.18 1.08
2 4 6 18 1 6 0 1 3+ 2+ 0 0 1 2 1 1 0 1 1 1 0 0 0 0 0 0 1,3,5 1.26 1.46 1.36 1.18 1.08 1.26 1.46 1.36 1.18 1.08
3 0 1.26 1.46 1.36 1.18 1.08 1.26 1.46 1.36 1.18 1.08
32 3864183 Vijay 33 M 1 1 6 24 1 2 0 1 4+ 2+ 0 1 1 2 0 0 0 0 0 0 0 0 0 0 0 0 1,2,3 1.11 1.18 1.2 1.04 0.6 0.95 1 1.08 0.9 0
2 0 6 6 1 4 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66
3 1.26 1.46 1.36 1.18 0.78 1.26 1.46 1.36 1.18 0.78
33 3068692 Banumathi 40 F 1 0 6 6 1 8 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66
2 2 6 18 1 6 0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.11 1.18 1.2 1.04 0.6 0.95 1 1.08 0.9 0
3 1.26 1.46 1.36 1.18 0.78 1.26 1.46 1.36 1.18 0.78
34 3784005 Deepika 16 F 1 4 6 18 1 9 0 1 3+ 2+ 0 0 1 2 1 1 0 0 0 2 0 0 0 0 0 0 1,2,3 1.11 1.3 1.36 1.18 0.78 0.95 1.18 1.08 0.9 0.6
2 4 618 1 7 0 1 3+ 2+ 0 0 1 2 1 1 0 0 0 2 0 0 0 0 0 0 1,2,3 1.11 1.3 1.36 1.18 0.78 0.95 1.18 1.08 0.9 0.6
3 0 1.11 1.3 1.36 1.18 0.78 0.95 1.18 1.08 0.9 0.6
35 3868073 Rajeswari 25 F 1 3 6 12 1 2 0 0 0 0 0 0 1 1 1 0 0 1 2 2 0 0 0 0 0 0 5 1.56 1.76 1.81 1.63 1.36 1.56 1.76 1.81 1.63 1.36
2 0 6 6 1 4 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66
3 1.56 1.9 1.81 1.78 1.52 1.56 1.9 1.81 1.78 1.52
36 3864443 Murugan 33 M 1 1 6 9 1 7 0 0 2+ 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,2 1.56 1.9 1.81 1.63 1.36 1.56 1.6 1.65 1.48 1.23
2 1 6 9 1 6 0 0 2+ 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,2 1.56 1.9 1.81 1.63 1.36 1.56 1.6 1.65 1.48 1.23
3 1.56 1.9 1.81 1.63 1.36 1.56 1.6 1.65 1.48 1.23
37 3872753 Barathkumar 25 M 1 0 6 12   1 9 0 0 0 0 0 0 1 1 1 0 0 1 2 2 0 0 0 0 0 0 2,5 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.48 1.23
2 3 6 6 1 4 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 2.11 1.78 1.52 1.7 2.06 2.11 1.78 1.52
3 1.56 1.76 1.81 1.63 1.23 1.56 1.76 1.81 1.63 1.23
38 3871184 Manikandan 30 M 1 4 6 18 1 5 0 1 3+ 2+ 0 0 1 2 1 1 0 1 1 1 0 0 0 0 0 0 1,3,5 1.26 1.46 1.36 1.18 1.08 1.26 1.46 1.36 1.18 1.08
2 4 6 18 1 6 0 1 3+ 2+ 0 0 1 2 1 1 0 1 1 1 0 0 0 0 0 0 1,3,5 1.26 1.46 1.36 1.18 1.08 1.26 1.46 1.36 1.18 1.08
3 1.26 1.46 1.36 1.18 1.08 1.26 1.46 1.36 1.18 1.08
39 3842057 Jency George 32 F 1 2 6 12 1 9 0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.81 1.63 1.36 1.4 1.6 1.65 1.48 1.23
2 2 6 12 1 4 0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.81 1.63 1.36 1.4 1.6 1.65 1.48 1.23
3 1.56 1.76 1.81 1.63 1.36 1.4 1.6 1.65 1.48 1.23
40 3865371 Shibukumar 37 M 1 0 6 6 1 2 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52
2 1 6 24 1 6 0 1 3+ 2+ 0 0 1 2 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.26 1.46 1.36 1.04 0.78 1.26 1.46 1.36 1.04 0.78
3 1.4 1.6 1.65 1.34 1.23 1.4 1.6 1.65 1.34 1.08
41 1480890 Ramadevi 41 F 1 4  6 12 1 8 1 1 3+ 2+ 0 0 1 2 1 1 1 0 2 2 0 0 0 0 0 0 1,2,3 1.4 1.6 1.65 1.48 1.23 1.26 1.46 1.52 1.34 0.9
2 4  6 12 1 7 1 1 3+ 2+ 0 0 1 2 1 1 1 0 2 2 0 0 0 0 0 0 1,2,3 1.4 1.6 1.65 1.48 1.23 1.26 1.46 1.52 1.34 0.9
3 1.4 1.6 1.65 1.48 1.23 1.26 1.46 1.52 1.34 0.9
42 3865332 Jeyakumar 27 M 1 1 6 24 1 1 0 1 4+ 2+ 0 1 1 2 0 0 0 0 0 0 0 0 0 0 0 0 1,2,3 1.11 1.18 1.2 1.04 0.6 0.95 1 1.08 0.9 0
2 0 6 6 1 6 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66
3 1.26 1.46 1.36 1.18 0.78 1.26 1.46 1.36 1.18 0.78
43 3864400 Jeya 39 F 1 3 6 12   1 8 0 0 0 0 0 0 1 1 1 0 0 1 2 2 0 0 0 0 0 0 2,5 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.48 1.23
2 0 6 6 1 4 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 2.11 1.78 1.52 1.7 2.06 2.11 1.78 1.52
3 1.56 1.76 1.81 1.63 1.23 1.56 1.76 1.81 1.63 1.23
44 3866459 Eswari 33 F 1 4 6 18 2 0 0 1 3+ 2+ 0 0 1 2 1 1 0 1 1 1 0 0 0 0 0 0 1,3,5 1.26 1.46 1.36 1.18 1.08 1.26 1.46 1.36 1.18 1.08
2 4 6 18 1 8 0 1 3+ 2+ 0 0 1 2 1 1 0 1 1 1 0 0 0 0 0 0 1,3,5 1.26 1.46 1.36 1.18 1.08 1.26 1.46 1.36 1.18 1.08
3 1.26 1.46 1.36 1.18 1.08 1.26 1.46 1.36 1.18 1.08
45 3866468 Thiyagarajan 45 M 1 1 6 9 1 7 0 1 2+ 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.34 1.23
2 1 6 9 1 2 0 1 2+ 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.34 1.23
3 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.34 1.23
46 1485607 Siva 27 M 1 0 6 6 1 4 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52
2 3 6 24 1 2 0 0 0 0 0 0 1 2 1 0 0 0 2 2 0 0 0 0 0 0 1,5 1.11 1.18 1.2 1.04 0.6 1.11 1.18 1.2 0.9 0.6
3 1.26 1.6 1.36 1.34 0.9 1.26 1.6 1.36 1.34 0.9
47 2704820 Ashwin 38 M 1 2 6 12 1 6 0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.81 1.63 1.36 1.4 1.6 1.65 1.48 1.23
2 2 6 12 1 5 0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.81 1.63 1.36 1.4 1.6 1.65 1.48 1.23
3 1.56 1.76 1.81 1.63 1.36 1.4 1.6 1.65 1.48 1.23
48 3872775 Saraswathy 40 F 1 4 6 36 1 9 1 1 3+ 2+ 0 0 1 2 1 1 1 0 0 2 0 0 0 0 0 0 1,2,3 1.11 1.18 1.2 1.04 0 0.95 1 1.08 0 0
2 4 6 24 1 7 1 1 3+ 2+ 0 0 1 2 1 1 1 0 0 2 0 0 0 0 0 0 1,2,3 1.11 1.18 1.2 1.04 0 0.95 1 1.08 0 0
3 1.11 1.18 1.2 1.04 0 0.95 1 1.08 0 0
49 3865473 Nagaraj 18 M 1 3 6 12   1 2 0 0 0 0 0 0 1 1 1 0 0 1 2 2 0 0 0 0 0 0 2,5 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.48 1.23
2 0 6 6 1 6 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 2.11 1.78 1.52 1.7 2.06 2.11 1.78 1.52
3 1.56 1.76 1.81 1.63 1.23 1.56 1.76 1.81 1.63 1.23
50 3859659 Vijayalakshmi 32 F 1 1 6 24 1 7 0 1 4+ 2+ 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,3 1.26 1.3 1.2 1.04 0.78 1.11 1.3 1.2 0 0
2 0 6 6 1 5 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.52 1.85 2.06 2.11 1.93 1.52
3 1.4 1.6 1.65 1.34 1.08 1.4 1.6 1.52 1.34 0.9
51 1472017 Lakshmanan 36 M 1 4 6 24 1  2 0 0 3+ 2+ 0 1 1 2 1 0 0 1 1 0 0 0 0 0 0 0 1,2,3,4 1.11 1.3 1.36 1.18 0.78 1.11 1.3 1.36 1.18 0.78
2 4 6 36 1 5 0 1 3+ 2+ 0 1 1 2 1 0 0 1 1 0 0 0 0 0 0 0 1,2,3,4 1.11 1.3 1.36 1.18 0.78 1.11 1.3 1.36 1.18 0.78
3 1.11 1.3 1.36 1.18 0.78 1.11 1.3 1.36 1.18 0.78
52 3864233 Sahira banu 18 F 1 0 6 6 1 2 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52
2 3 6 24 1 6 0 0 0 0 0 0 1 2 1 0 0 0 2 2 0 0 0 0 0 0 1,5 1.11 1.18 1.2 1.04 0.6 1.11 1.18 1.2 0.9 0.6
3 1.26 1.6 1.36 1.34 0.9 1.26 1.6 1.36 1.34 0.9
53 3872079 Madhu bharathi 40 F 1 2 6 18 1 8 0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.26 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.18 0.78
2 2 6 12 1 5 0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.26 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.18 0.78
3 1.26 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.18 0.78
54 3363144 Purushothaman 42 M 1 4 6 36 1 7 1 1 3+ 2+ 0 0 1 2 1 1 1 1 2 2 0 0 0 0 0 0 1,2,3,5 1.11 1.3 1.36 1.18 0.9 0.95 1.18 1.2 1.04 0.78
2 4 6 36 1 6 1 1 3+ 2+ 0 0 1 2 1 1 1 1 2 2 0 0 0 0 0 0 1,2,3,5 1.11 1.3 1.36 1.18 0.9 0.95 1.18 1.2 1.04 0.78
3 1.11 1.3 1.36 1.18 0.9 0.95 1.18 1.2 1.04 0.78
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0.95 1.18 1.2 0 0 0.85 1 1.08 0 0 6 9 1 2
1.7 1.9 1.95 1.78 1.36 1.7 1.9 1.95 1.78 1.36 6 6 1 6
1.56 1.76 1.65 1.34 1.08 1.4 1.6 1.65 1.48 1.23 0 0 0 0 0 2 0 0 0 0 0 1 1 0 2 2 0 0 0 0 0 2 1 0 0 1 1 2 2 2 2 1 1
1.26 1.3 1.36 1.18 0.78 1.11 1.18 1.2 1.04 0 6 9 1 8
1.26 1.3 1.36 1.18 0.78 1.11 1.18 1.2 1.04 0 6 9 1 7
1.26 1.3 1.36 1.18 0.78 1.11 1.18 1.2 1.04 0 0 0 0 0 0 2 1 1 2 0 0 1 1 0 3 3 1 0 0 0 0 2 1 1 1 1 2 2 2 2 2 1 2
1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 6 6 1 1
1.4 1.6 1.65 1.34 1.08 1.26 1.46 1.52 1.18 0 6 9 1 6
1.56 1.6 1.81 1.48 1.23 1.56 1.6 1.52 1.34 1.08 1 1 0 1 0 2 1 1 1 0 0 2 2 0 2 2 2 0 0 0 0 2 2 1 1 2 2 2 2 2 1 1 1
0.95 1.18 1.2 0 0 0.85 0 0 0 0 6 12 1 8
0.95 1.18 1.2 0 0 0.85 0 0 0 0 6 12 1 4
0.95 1.18 1.2 0 0 0 0 0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 2 2 1 2 3 3 3 3 2 3 3
1.7 1.9 1.95 1.63 1.52 1.7 1.9 1.81 1.63 1.36 6 6 2 0
1.4 1.46 1.52 1.34 0.9 1.11 1.3 1.36 1.18 0.78 6 6 1 8
1.46 1.6 1.65 1.48 1.23 1.26 1.46 1.52 1.34 1.08 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 1 0 0 0
1.11 1.18 1.2 0.9 0.6 1.11 1 1.08 0 0 6 9 1 7
1.85 2.06 2.11 1.93 1.52 1.85 2.06 2.11 1.93 1.52 6 6 1 2
1.4 1.46 1.52 1.18 0.9 1.4 1.3 1.36 1.04 0.6 0 0 0 0 1 2 0 0 2 1 0 0 2 1 2 2 0 0 0 0 0 2 2 1 0 1 2 2 2 2 2 1 2
1.56 1.46 1.52 1.18 0.9 1.56 1.3 1.36 1.04 0.78 6 6 1 4
1.7 1.9 1.81 1.63 1.36 1.7 1.9 1.81 1.63 1.36 6 6 1 2
1.56 1.6 1.52 1.34 1.08 1.56 1.46 1.52 1.18 0.78 0 0 0 0 0 2 0 0 1 0 0 1 0 2 2 0 0 0 0 0 0 2 1 1 0 1 2 2 2 2 1 1 2
1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52 6 6 1 6
0.95 1 1.08 0 0 0.85 1 0 0 0 6 12 1 5
1.26 1.6 1.36 1.34 0.9 1.26 1.6 1.2 0.9 0.6 1 1 1 1 1 2 1 1 2 1 2 2 2 3 3 1 1 1 1 1 3 3 3 2 3 3 3 3 3 3 3 3 3
0.95 1.18 1.2 0 0 0.95 1 0 0 0 6 36 1 9
0.95 1.18 0 0 0 0.95 1 0 0 0 6 36 1 7
0.95 1.18 0 0 0 0.95 1 0 0 0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
1.26 1.46 1.36 1.18 0.9 1.11 1.18 1.2 1.04 0.78 6 9 1 2
1.26 1.46 1.36 1.18 0.9 1.11 1.18 1.2 1.04 0.78 6 9 1 6
1.26 1.46 1.36 1.18 0.9 1.11 1.18 1.2 1.04 0.78 1 1 1 1 1 2 1 1 1 1 1 2 2 1 2 2 1 0 0 0 0 2 2 1 1 1 2 2 2 2 2 2 2
1.26 1.46 1.36 1.18 0.78 1.26 1.46 1.2 1.04 0.78 6 12 1 7
1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52 6 6 1 5
1.4 1.6 1.52 1.18 1.08 1.4 1.6 1.52 1.18 0.9 1 1 1 1 1 3 1 1 2 1 1 2 2 2 2 2 1 1 1 1 1 3 2 1 1 2 3 3 3 3 2 1 3
1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.63 1.36 6 6 1  2
1.11 1.3 1.2 1.04 0.78 0.95 1.18 1.2 0 0 6 36 1 5
1.4 1.6 1.65 1.18 0.9 1.4 1.46 1.65 1.18 0.78 1 1 1 1 1 2 2 2 2 2 1 2 2 2 2 2 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2
0.95 1 1.08 0 0 0.85 1 0 0 0 6 12 1 2
0.95 1 1.08 0 0 0.85 0 0 0 0 6 9 1 6
0.95 1 1.08 0 0 0.85 0 0 0 0 2 2 2 2 2 3 2 3 3 2 2 3 3 3 3 1 1 2 1 1 1 3 3 3 2 3 3 3 3 3 3 3 3
1.4 1.6 1.81 1.48 1.23 1.4 1.6 1.81 1.48 1.23 6 9 1 8
1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66 6 6 1 5
1.56 1.76 1.81 1.63 1.36 1.56 1.76 1.81 1.48 1.23 1 1 1 1 1 1 2 1 1 2 1 1 1 1 1 1 1 0 0 0 0 2 2 1 1 2 2 2 2 2 2 2 2
1.4 1.6 1.52 1.34 1.23 1.4 1.46 1.52 1.34 1.08 6 6 1 7
1.4 1.6 1.52 1.34 1.23 1.4 1.46 1.52 1.34 1.08 6 6 1 6
1.4 1.6 1.52 1.34 1.23 1.4 1.46 1.52 1.34 1.08 1 1 1 1 1 2 1 2 2 1 1 2 2 2 2 2 1 0 0 0 0 2 2 1 1 2 2 2 2 2 2 2 2
1.56 1.46 1.52 1.18 0.9 1.56 1.3 1.36 1.04 0.78 6 6 2 0
1.7 1.9 1.81 1.63 1.36 1.7 1.9 1.81 1.63 1.36 6 6 1 7
1.56 1.6 1.52 1.34 1.08 1.56 1.46 1.52 1.18 0.78 1 1 1 1 1 2 1 2 2 1 1 2 2 2 2 2 1 0 0 0 0 2 2 1 1 2 2 2 2 2 2 2 2
1.11 1.3 1.36 1.18 0.78 1.11 1.18 1.08 0 0 6 9 1 2
1.11 1.3 1.36 1.36 1.36 1.36 1.36 1.36 1.36 1.36 6 9 1 4
1.11 1.3 1.36 1.36 1.36 1.36 1.36 1.36 1.36 1.36 1 1 1 1 1 3 3 3 3 3 2 2 3 3 3 3 1 1 1 1 1 3 3 3 2 3 3 3 3 3 3 3 3
1.26 1.3 1.36 0 0 1.26 1.18 0 0 0 6 9 1 6
1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66 6 6 1 2
1.4 1.6 1.52 1.18 0.9 1.4 1.46 1.36 1.04 0.78 1 1 1 1 1 2 1 1 2 1 1 1 1 1 2 2 1 1 0 0 0 2 1 1 1 2 2 2 2 2 2 2 2
0.95 1.18 1.2 1.04 0.6 0.85 1 1.08 0 0 6 36 2 0
0.95 1.18 1.2 1.04 0.6 0.85 1 1.08 0 0 6 36 1 8
0.95 1.18 1.2 1.04 0.6 0.85 1 1.08 0 0 1 1 1 1 1 2 1 2 2 2 1 2 2 2 2 2 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2
N
C
T
CS (Night)
Without glare General functioning scale Visual symptoms scalePsychosocial impact scale
B
C
V
AWith glare
1.4 1.6 1.65 1.48 1.23 1.4 1.46 1.52 1.34 1.08 6 9 1 4
1.4 1.6 1.65 1.48 1.23 1.4 1.46 1.52 1.34 1.08 6 9 1 7
1.4 1.6 1.65 1.48 1.23 1.4 1.46 1.52 1.34 1.08 1 1 1 1 1 2 1 1 2 1 1 1 2 1 2 2 0 0 0 0 0 2 1 1 1 2 2 2 2 2 2 2 2
1.85 2.06 2.11 1.93 1.52 1.85 2.06 2.11 1.93 1.52 6 6 1 6
1.11 1.18 1.2 0.9 0.6 1.11 1 1.08 0 0 6 9 1 5
1.4 1.46 1.52 1.18 0.9 1.4 1.3 1.36 1.04 0.6 0 0 0 0 1 2 0 0 2 1 0 0 2 1 2 2 0 0 0 0 0 2 2 1 0 1 2 2 2 2 2 1 2
1.56 1.46 1.52 1.18 0.9 1.56 1.3 1.36 1.04 0.78 6 6 1 4
1.7 1.9 1.81 1.63 1.36 1.7 1.9 1.81 1.63 1.36 6 6 1 6
1.56 1.6 1.52 1.34 1.08 1.56 1.46 1.52 1.18 0.78 0 0 0 0 0 2 0 0 1 0 0 1 0 2 2 0 0 0 0 0 0 2 1 1 0 1 2 2 2 2 1 1 2
0.95 1 1.08 0 0 0.85 1 0 0 0 6 12 1 2
1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52 6 6 1 4
1.26 1.6 1.36 1.34 0.9 1.26 1.6 1.2 0.9 0.6 1 1 1 1 1 2 1 1 2 1 2 2 2 3 3 1 1 1 1 1 3 3 3 2 3 3 3 3 3 3 3 3 3
0.95 1 1.08 0 0 0.85 1 0 0 0 6 12 1 8
0.95 1 1.08 0 0 0.85 0 0 0 0 6 9 1 6
0.95 1 1.08 0 0 0.85 0 0 0 0 2 2 2 2 2 3 2 3 3 2 2 3 3 3 3 1 1 2 1 1 1 3 3 3 2 3 3 3 3 3 3 3 3
1.26 1.46 1.36 1.18 0.9 1.11 1.18 1.2 0 0 6 9 1 9
1.26 1.46 1.36 1.18 0.9 1.11 1.18 1.2 0 0 6 9 1 7
1.26 1.46 1.36 1.18 0.9 1.11 1.18 1.2 0 0 1 1 1 1 1 2 1 1 1 1 1 2 2 1 2 2 1 0 0 0 0 2 2 1 1 1 2 2 2 2 2 2 2
1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52 6 6 1 2
1.26 1.46 1.36 1.18 0.78 1.26 1.46 1.2 1.04 0.78 6 12 1 4
1.4 1.6 1.52 1.18 1.08 1.4 1.6 1.52 1.18 0.9 1 1 1 1 1 3 1 1 2 1 1 2 2 2 2 2 1 1 1 1 1 3 2 1 1 2 3 3 3 3 2 1 3
1.11 1.3 1.2 1.04 0.78 0.95 1.18 1.2 0 0 6 36 1 7
1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.63 1.36 6 6 1 6
1.4 1.6 1.65 1.18 0.9 1.4 1.46 1.65 1.18 0.78 1 1 1 1 1 2 2 2 2 2 1 2 2 2 2 2 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2
0.95 1.18 1.2 0 0 0.95 1 0 0 0 6 36 1 9
0.95 1.18 0 0 0 0.95 1 0 0 0 6 36 1 4
0.95 1.18 0 0 0 0.95 1 0 0 0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66 6 6 1 5
1.4 1.6 1.81 1.48 1.23 1.4 1.6 1.81 1.48 1.23 6 9 1 6
1.56 1.76 1.81 1.63 1.36 1.56 1.76 1.81 1.48 1.23 1 1 1 1 1 1 2 1 1 2 1 1 1 1 1 1 1 0 0 0 0 2 2 1 1 2 2 2 2 2 2 2 2
1.4 1.6 1.52 1.34 1.23 1.4 1.46 1.52 1.34 1.08 6 6 1 9
1.4 1.6 1.52 1.34 1.23 1.4 1.46 1.52 1.34 1.08 6 6 1 4
1.4 1.6 1.52 1.34 1.23 1.4 1.46 1.52 1.34 1.08 1 1 1 1 1 2 1 2 2 1 1 2 2 2 2 2 1 0 0 0 0 2 2 1 1 2 2 2 2 2 2 2 2
1.11 1.18 1.2 1.04 0.78 0.85 1 1.08 0 0 6 24 1 2
1.11 1.18 1.2 1.04 0.78 0 0 0 0 0 6 24 1 6
1.11 1.18 1.2 1.04 0.78 0 0 0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
0 0 0 0 0 0 0 0 0 0 6 9 1 8
1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66 6 6 1 7
1.11 1.3 1.36 1.18 0.9 1.11 1.3 1.36 1.18 0.9 1 1 1 1 1 3 2 3 3 2 3 3 2 3 3 1 1 1 2 1 3 3 3 3 3 3 3 3 3 3 3 3
1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66 6 6 1 1
0 0 0 0 0 0 0 0 0 0 6 18 1 6
1.11 1.3 1.36 1.18 0.9 1.11 1.3 1.36 1.18 0.9 1 1 1 1 1 3 1 3 3 1 3 3 1 3 3 1 1 1 1 1 3 3 3 3 3 3 3 3 3 3 3 3
0.95 1 0 0 0 0 0 0 0 0 6 9 1 8
0.95 1 0 0 0 0 0 0 0 0 6 9  1 4
0.95 1 0 0 0 0 0 0 0 0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
1.4 1.46 1.52 1.34 1.08 1.11 1.3 1.36 1.18 0.9 6 24 2 0
1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66 6 6 1 8
1.56 1.76 1.81 1.63 1.23 1.56 1.76 1.81 1.63 1.23 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
1.26 1.46 1.52 1.34 1.08 1.26 1.46 1.36 1.18 0.9 6 9 1 7
1.26 1.46 1.52 1.34 1.08 1.26 1.46 1.36 1.18 0.9 6 9 1 2
1.26 1.46 1.52 1.34 1.08 1.26 1.46 1.36 1.18 0.9 1 1 1 1 1 2 1 2 2 1 1 1 2 2 1 2 2 1 1 1 1 2 2 2 1 2 2 2 2 2 2 2 2
1.26 1.46 1.52 1.34 1.08 1.26 1.3 1.36 1.18 0.9 6 18 1 4
1.7 2.06 2.11 1.78 1.52 1.7 2.06 2.11 1.78 1.52 6 6 1 2
1.4 4.6 1.65 1.48 1.23 1.4 4.6 1.65 1.48 1.23 1 1 1 1 1 2 1 2 2 1 1 1 2 2 1 2 2 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2
1.11 1.18 1.2 1.04 0.78 0.85 1 1.08 0 0 6 24 1 6
1.11 1.18 1.2 1.04 0.78 0 0 0 0 0 6 24 1 5
1.11 1.18 1.2 1.04 0.78 0 0 0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
1.4 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.34 1.08 6 6 1 9
1.4 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.34 1.08 6 6 1 7
1.4 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.34 1.08 2 2 2 2 2 3 2 3 1 1 1 3 3 3 1 3 3 3 2 1 1 3 3 3 2 3 3 3 3 3 3 3 3
1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.63 1.36 6 6 1 2
1.11 1.3 1.2 1.04 0.78 0.95 1.18 1.2 0 0 6 36 1 6
1.4 1.6 1.65 1.18 0.9 1.4 1.46 1.65 1.18 0.78 1 1 1 1 1 2 2 2 2 2 1 2 2 2 2 2 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2
0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0 0 6 60 1 7
0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0 0 6 60 1 5
0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 2 3 2 3 3 3 3 3 3 3 3
0 0 0 0 0 0 0 0 0 0 6 9 1  2
1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66 6 6 1 5
1.11 1.3 1.36 1.18 0.9 1.11 1.3 1.36 1.18 0.9 1 1 1 1 1 3 2 3 3 2 3 3 2 3 3 1 1 1 2 1 3 3 3 3 3 3 3 3 3 3 3 3
1.26 1.46 1.52 1.34 1.08 1.26 1.3 1.36 1.18 0.9 6 18 1 2
1.7 2.06 2.11 1.78 1.52 1.7 2.06 2.11 1.78 1.52 6 6 1 6
1.4 4.6 1.65 1.48 1.23 1.4 4.6 1.65 1.48 1.23 1 1 1 1 1 2 1 2 2 1 1 1 2 2 1 2 2 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2
1.11 1.18 1.2 1.04 0.78 0.85 1 1.08 0 0 6 24 1 8
1.11 1.18 1.2 1.04 0.78 0 0 0 0 0 6 24 1 5
1.11 1.18 1.2 1.04 0.78 0 0 0 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
1.4 1.6 1.52 1.34 1.23 1.4 1.46 1.52 1.34 1.08 6 6 1 7
1.4 1.6 1.52 1.34 1.23 1.4 1.46 1.52 1.34 1.08 6 6 1 6
1.4 1.6 1.52 1.34 1.23 1.4 1.46 1.52 1.34 1.08 1 1 1 1 1 2 1 2 2 1 1 2 2 2 2 2 1 0 0 0 0 2 2 1 1 2 2 2 2 2 2 2 2
1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52 6 6 1 9
0.95 1 1.08 0 0 0.85 1 0 0 0 6 12 1 7
1.26 1.6 1.36 1.34 0.9 1.26 1.6 1.2 0.9 0.6 1 1 1 1 1 2 1 1 2 1 2 2 2 3 3 1 1 1 1 1 3 3 3 2 3 3 3 3 3 3 3 3 3
1.4 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.34 1.08 6 6 1 2
1.4 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.34 1.08 6 6 1 6
1.4 1.46 1.52 1.34 1.08 1.26 1.46 1.52 1.34 1.08 2 2 2 2 2 3 2 3 1 1 1 3 3 3 1 3 3 3 2 1 1 3 3 3 2 3 3 3 3 3 3 3 3
0.95 1 1.08 0 0 0.85 1 0 0 0 6 12 1 7
0.95 1 1.08 0 0 0.85 0 0 0 0 6 9 1 5
0.95 1 1.08 0 0 0.85 0 0 0 0 2 2 2 2 2 3 2 3 3 2 2 3 3 3 3 1 1 2 1 1 1 3 3 3 2 3 3 3 3 3 3 3 3
1.26 1.46 1.52 1.34 1.08 1.26 1.3 1.36 1.18 0.9 6 18 1  2
1.7 2.06 2.11 1.78 1.52 1.7 2.06 2.11 1.78 1.52 6 6 1 5
1.4 4.6 1.65 1.48 1.23 1.4 4.6 1.65 1.48 1.23 1 1 1 1 1 2 1 2 2 1 1 1 2 2 1 2 2 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2
1.11 1.18 1.2 0.9 0.6 1.11 1 1.08 0 0 6 9 1 2
1.85 2.06 2.11 1.93 1.52 1.85 2.06 2.11 1.93 1.52 6 6 1 6
1.4 1.46 1.52 1.18 0.9 1.4 1.3 1.36 1.04 0.6 0 0 0 0 1 2 0 0 2 1 0 0 2 1 2 2 0 0 0 0 0 2 2 1 0 1 2 2 2 2 2 1 2
0.95 1.18 1.2 0 0 0.95 1 0 0 0 6 36 1 8
0.95 1.18 0 0 0 0.95 1 0 0 0 6 36 1 5
0.95 1.18 0 0 0 0.95 1 0 0 0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52 6 6 1 7
0.95 1 1.08 0 0 0.85 1 0 0 0 6 12 1 6
1.26 1.6 1.36 1.34 0.9 1.26 1.6 1.2 0.9 0.6 1 1 1 1 1 2 1 1 2 1 2 2 2 3 3 1 1 1 1 1 3 3 3 2 3 3 3 3 3 3 3 3 3
1.11 1.3 1.36 1.18 0.78 1.11 1.18 1.08 0 0 6 9 2 0
1.11 1.3 1.36 1.36 1.36 1.36 1.36 1.36 1.36 1.36 6 9 1 7
1.11 1.3 1.36 1.36 1.36 1.36 1.36 1.36 1.36 1.36 1 1 1 1 1 3 3 3 3 3 2 2 3 3 3 3 1 1 1 1 1 3 3 3 2 3 3 3 3 3 3 3 3
0.85 1 0 0 0 0 0 0 0 0 6 12 1 2
0.85 1 0 0 0 0 0 0 0 0  6 9 1 4
0.85 1 0 0 0 0 0 0 0 0 2 2 2 2 2 3 2 3 3 2 2 2 2 3 3 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3
1.
5 3 6 12 18 1.
5 3 6 12 18 1.
5
0 0 1+ 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.56 1.76 1.81 1.63 1.23 1.4 1.6 1.65 1.34 1.08 1.4
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.78 1.36 1.7 1.9 1.95 1.78 1.36 1.7
1.7 1.76 1.81 1.63 1.36 1.7 1.76 1.65 1.63 1.36 1.7
0 0 0 0 0 0 1 1 1+ 0 0 0 0 0 0 0 0 0 0 0 1 1.56 1.76 1.65 1.48 1.08 1.56 1.76 1.65 1.34 1.08 1.56
0 0 0 0 0 0 1 1 1+ 0 0 0 0 0 0 0 0 0 0 0 1 1.56 1.76 1.65 1.48 1.08 1.56 1.76 1.65 1.34 1.08 1.56
1.7 1.76 1.81 1.63 1.36 1.56 1.76 1.65 1.34 1.08 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.7
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.56 1.76 1.81 1.63 1.36 1.56 1.76 1.81 1.63 1.23 1.56
1.56 1.76 1.65 1.63 1.23 1.4 1.6 1.65 1.48 1.08 1.56
0 0 1+ 1+ 0 0 1 2 1+ 0 0 0 0 0 0 0 0 0 0 0 1,2 1.4 1.6 1.65 1.48 1.08 1.26 1.46 1.52 1.34 1.08 1.26
0 0 1+ 1+ 0 0 1 2 1+ 0 0 0 0 0 0 0 0 0 0 0 1,2 1.4 1.6 1.65 1.48 0.9 1.26 1.46 1.52 1.34 1.08 1.26
1.4 1.6 1.65 1.48 0.9 1.26 1.46 1.36 1.18 0.78 1.26
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.63 1.52 1.7 1.9 1.81 1.78 1.52 1.7
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.76 1.81 1.63 1.36 1.56 1.6 1.65 1.48 1.23 1.56
1.7 1.76 1.81 1.48 1.36 1.56 1.76 1.65 1.63 1.23 1.56
0 0 0 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.56 1.76 1.81 1.48 1.23 1.4 1.6 1.65 1.48 1.08 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.52 1.85 2.06 2.11 1.93 1.52 1.85
1.7 1.9 1.81 1.63 1.23 1.7 1.9 1.81 1.63 1.23 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.76 1.65 1.48 1.23 1.7 1.6 1.65 1.34 1.08 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.81 1.63 1.36 1.7 1.9 1.81 1.63 1.36 1.7
1.56 1.76 1.65 1.48 1.23 1.56 1.76 1.65 1.34 1.23 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52 1.7
0 0 0 0 0 0 1 2 1 0 0 0 0 2 0 0 0 0 0 0 1,5 1.26 1.3 1.36 1.18 0.9 1.26 1.3 1.36 1.18 0.9 1.26
1.4 1.6 1.65 1.34 1.08 1.4 1.6 1.65 1.34 1.08 1.4
0 0 2+ 2+ 0 0 1 2 1 0 0 1 1 0 0 0 0 1 0 0 1,2,3,4 0.95 1.18 1.2 1.04 0 0.95 1.18 1.2 1.04 0 0.85
0 1 2+ 2+ 0 0 1 2 1 0 0 1 1 0 0 0 0 1 0 0 1,2,3,4 0.95 1.18 1.2 0 0 0.95 1.18 1.2 0 0 0.85
0.95 1.18 1.2 0 0 0.95 1.18 1.2 0 0 0.85
0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.48 1.23 1.26
0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.48 1.23 1.26
1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.48 1.23 1.26
0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.81 1.48 1.36 1.56 1.76 1.81 1.48 1.36 1.4
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52 1.7
1.56 1.6 1.65 1.48 1.08 1.56 1.6 1.65 1.48 1.08 1.4
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52 1.7
0 1 3+ 2+ 1 0 3 2 0 0 0 0 0 0 0 0 0 0 0 0 1,2,3 1.11 1.3 1.2 1.04 0.78 1.11 1.3 1.2 1.04 0.78 0.95
1.26 1.52 1.65 1.34 0.9 1.26 1.52 1.52 1.18 0.9 1.11
0 1 1+ 1+ 0 0 1 2 1 0 0 0 0 2 0 0 0 0 0 0 1,2 1.4 1.6 1.65 1.48 1.08 1.26 1.3 1.36 1.18 0.9 1.26
0 1 1+ 1+ 0 0 1 2 1 0 0 0 0 2 0 0 0 0 0 0 1,2 1.4 1.6 1.65 1.48 1.08 1.26 1.3 1.36 1.18 0.9 1.26
1.11 1.18 1.2 1.04 0 1.26 1.3 1.36 1.18 0.9 1.26
0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 1,2 1.7 1.76 1.81 1.78 1.36 1.7 1.76 1.81 1.63 1.36 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66 1.85
1.7 1.76 1.81 1.48 1.36 1.7 1.76 1.81 1.48 1.36 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.7
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.7
1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.7
0 0 0 0 0 0 4 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.7
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.7
1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.7
0 0 0 0 0 0 1 2 1 0 0 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.81 1.63 1.52 1.56 1.76 1.65 1.63 1.36 1.4
0 0 0 0 0 0 1 2 1 0 0 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.81 1.63 1.52 1.56 1.76 1.65 1.63 1.36 1.4
1.56 1.76 1.81 1.63 1.52 1.56 1.76 1.65 1.63 1.36 1.4
0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 2,5 1.56 1.76 1.81 1.63 1.52 1.56 1.76 1.81 1.63 1.52 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66 1.85
1.7 1.76 1.81 1.63 1.23 1.7 1.76 1.81 1.63 1.23 1.56
0 0 3+ 2+ 0 0 1 2 1 1 1 1 2 0 0 0 1 0 0 0 1,2,3,4 0.95 1.18 1.2 0.9 0.6 0.95 1.18 1.2 0.9 0.6 0
0 0 3+ 2+ 0 0 1 2 1 1 1 1 2 0 0 0 1 0 0 0 1,2,3,4 0.95 1.18 1.2 0.9 0.6 0.95 1.18 1.2 0.9 0.6 0
1.26 1.46 1.36 1.18 0.9 1.11 1.3 1.36 1.18 0.6 0
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Without glare With glare
1 Month Follow Up - Post Treatment
Contrast Sensitivity
0 0 1+ 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1.56 1.76 1.95 1.63 1.36 1.56 1.76 1.95 1.63 1.36 1.56
0 0 1+ 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1.56 1.76 1.95 1.63 1.36 1.56 1.76 1.95 1.63 1.36 1.56
1.56 1.76 1.95 1.63 1.36 1.56 1.76 1.95 1.63 1.36 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.52 1.85 2.06 2.11 1.93 1.52 1.85
0 0 0 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.56 1.76 1.81 1.48 1.23 1.4 1.6 1.65 1.48 1.08 1.56
1.7 1.9 1.81 1.63 1.23 1.7 1.9 1.81 1.63 1.23 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.76 1.65 1.48 1.23 1.7 1.6 1.65 1.34 1.08 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.81 1.63 1.36 1.7 1.9 1.81 1.63 1.36 1.7
1.56 1.76 1.65 1.48 1.23 1.56 1.76 1.65 1.34 1.23 1.56
0 0 0 0 0 0 1 2 1 0 0 0 0 2 0 0 0 0 0 0 1,5 1.26 1.3 1.36 1.18 0.9 1.26 1.3 1.36 1.18 0.9 1.26
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52 1.7
1.4 1.6 1.65 1.34 1.08 1.4 1.6 1.65 1.34 1.08 1.4
0 1 1+ 1+ 0 0 1 2 1 0 0 0 0 2 0 0 0 0 0 0 1,2 1.4 1.6 1.65 1.48 1.08 1.26 1.3 1.36 1.18 0.9 1.26
0 1 1+ 1+ 0 0 1 2 1 0 0 0 0 2 0 0 0 0 0 0 1,2 1.4 1.6 1.65 1.48 1.08 1.26 1.3 1.36 1.18 0.9 1.26
1.11 1.18 1.2 1.04 0 1.26 1.3 1.36 1.18 0.9 1.26
0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.48 1.23 1.26
0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.48 1.23 1.26
1.4 1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.48 1.23 1.26
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52 1.7
0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.81 1.48 1.36 1.56 1.76 1.81 1.48 1.36 1.4
1.56 1.6 1.65 1.48 1.08 1.56 1.6 1.65 1.48 1.08 1.4
0 1 3+ 2+ 1 0 3 2 0 0 0 0 0 0 0 0 0 0 0 0 1,2,3 1.11 1.3 1.2 1.04 0.78 1.11 1.3 1.2 1.04 0.78 0.95
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52 1.7
1.26 1.52 1.65 1.34 0.9 1.26 1.52 1.52 1.18 0.9 1.11
0 0 2+ 2+ 0 0 1 2 1 0 0 1 1 0 0 0 0 1 0 0 1,2,3,4 0.95 1.18 1.2 1.04 0 0.95 1.18 1.2 1.04 0 0.85
0 1 2+ 2+ 0 0 1 2 1 0 0 1 1 0 0 0 0 1 0 0 1,2,3,4 0.95 1.18 1.2 0 0 0.95 1.18 1.2 0 0 0.85
0.95 1.18 1.2 0 0 0.95 1.18 1.2 0 0 0.85
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66 1.85
0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 1,2 1.7 1.76 1.81 1.78 1.36 1.7 1.76 1.81 1.63 1.36 1.56
1.7 1.76 1.81 1.48 1.36 1.7 1.76 1.81 1.48 1.36 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.7
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.7
1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.7
0 1 3+ 2+ 0 0 1 2 1 1 0 1 1 1 0 1 0 1 0 0 1,3,5 0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0 0 0
0 1 3+ 2+ 0 0 1 2 1 1 0 1 1 1 0 1 0 1 0 0 1,3,5 0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0 0 0
0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0 0 0
0 0 0 1+ 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.81 1.63 1.36 1.56 1.76 1.81 1.63 1.36 1.4
0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.78 1.66 1.85 2.06 2.11 1.93 1.66 1.85
1.7 1.76 1.81 1.63 1.36 1.7 1.76 1.81 1.63 1.36 1.7
0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66 1.85
0 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0 0 0 1,2 1.11 1.18 1.2 1.04 0.6 0.95 1 1.08 0.9 0 0
0 1.46 1.36 1.18 0.78 1.26 1.46 1.36 1.18 0.78 1.11
0 0 0 1+ 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.65 1.34 1.08 1.56 1.76 1.65 1.34 1.08 1.4
0 0 0 1+ 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.65 1.34 1.08 1.56 1.76 1.65 1.34 1.08 1.4
1.56 1.76 1.65 1.34 1.08 1.56 1.76 1.65 1.34 1.08 1.4
0 0 0 0 0 0 1 2 1 0 0 1 2 2 1 0 0 0 0 0 2,5 0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0.9 0 0
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66 1.85
1.26 1.46 1.52 1.34 1.08 1.11 1.3 1.36 1.18 0.9 0.95
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.56
1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.56
0 0 0 0 0 0 1 2 1 0 0 1 2 2 1 0 0 1 0 0 2,5 0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0.9 0.6 0
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 2.11 1.78 1.52 1.7 2.06 2.11 1.78 1.52 1.7
1.11 1.3 1.52 1.18 0.9 1.11 1.3 1.52 1.18 0.9 1.11
0 1 3+ 2+ 0 0 1 2 1 1 0 1 1 1 0 1 0 1 0 0 1,3,5 0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0 0 0
0 1 3+ 2+ 0 0 1 2 1 1 0 1 1 1 0 1 0 1 0 0 1,3,5 0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0 0 0
0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0 0 0
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,2 1.7 1.9 1.95 1.63 1.36 1.7 1.9 1.95 1.63 1.36 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,2 1.7 1.9 1.95 1.63 1.36 1.7 1.9 1.95 1.63 1.36 1.56
1.7 1.9 1.95 1.63 1.36 1.7 1.9 1.95 1.63 1.36 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52 1.7
0 1 3+ 2+ 1 0 3 2 0 0 0 0 0 0 0 0 0 0 0 0 1,2,3 1.11 1.3 1.2 1.04 0.78 1.11 1.3 1.2 1.04 0.78 0.95
1.26 1.52 1.65 1.34 0.9 1.26 1.52 1.52 1.18 0.9 1.11
1 1 3+ 2+ 1 0 1 2 1 1 1 0 2 2 0 0 1 0 0 0 1,2,3,4 0.85 1 1.08 0 0 0 0 0 0 0 0
1 1 3+ 2+ 1 0 1 2 1 1 1 0 2 2 0 0 1 0 0 0 1,2,3,4 0.85 1 1.08 0 0 0 0 0 0 0 0
0.85 1 1.08 0 0 0 0 0 0 0 0
0 0 0 1+ 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.81 1.63 1.36 1.56 1.76 1.81 1.63 1.36 1.4
0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.78 1.66 1.85 2.06 2.11 1.93 1.66 1.85
1.7 1.76 1.81 1.63 1.36 1.7 1.76 1.81 1.63 1.36 1.7
0 0 0 0 0 0 1 2 1 0 0 1 2 2 1 0 0 1 0 0 2,5 0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0.9 0.6 0
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 2.11 1.78 1.52 1.7 2.06 2.11 1.78 1.52 1.7
1.11 1.3 1.52 1.18 0.9 1.11 1.3 1.52 1.18 0.9 1.11
0 1 3+ 2+ 0 0 1 2 1 1 0 1 1 1 0 1 0 1 0 0 1,3,5 0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0 0 0
0 1 3+ 2+ 0 0 1 2 1 1 0 1 1 1 0 1 0 1 0 0 1,3,5 0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0 0 0
0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0 0 0
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.7
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.7
1.7 1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 1.7
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52 1.7
0 0 0 0 0 0 1 2 1 0 0 0 0 2 0 0 0 0 0 0 1,5 1.26 1.3 1.36 1.18 0.9 1.26 1.3 1.36 1.18 0.9 1.26
1.4 1.6 1.65 1.34 1.08 1.4 1.6 1.65 1.34 1.08 1.4
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,2 1.7 1.9 1.95 1.63 1.36 1.7 1.9 1.95 1.63 1.36 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1,2 1.7 1.9 1.95 1.63 1.36 1.7 1.9 1.95 1.63 1.36 1.56
1.7 1.9 1.95 1.63 1.36 1.7 1.9 1.95 1.63 1.36 1.56
0 1 1+ 1+ 0 0 1 2 1 0 0 0 0 2 0 0 0 0 0 0 1,2 1.4 1.6 1.65 1.48 1.08 1.26 1.3 1.36 1.18 0.9 1.26
0 1 1+ 1+ 0 0 1 2 1 0 0 0 0 2 0 0 0 0 0 0 1,2 1.4 1.6 1.65 1.48 1.08 1.26 1.3 1.36 1.18 0.9 1.26
1.11 1.18 1.2 1.04 0 1.26 1.3 1.36 1.18 0.9 1.26
0 0 0 0 0 0 1 2 1 0 0 1 2 2 1 0 0 1 0 0 2,5 0.95 1.18 1.2 1.04 0.78 0.85 1 1.08 0.9 0.6 0
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 2.11 1.78 1.52 1.7 2.06 2.11 1.78 1.52 1.7
1.11 1.3 1.52 1.18 0.9 1.11 1.3 1.52 1.18 0.9 1.11
0 0 0 1+ 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.56 1.76 1.81 1.48 1.23 1.4 1.6 1.65 1.48 1.08 1.56
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.85 2.06 2.11 1.93 1.52 1.85 2.06 2.11 1.93 1.52 1.85
1.7 1.9 1.81 1.63 1.23 1.7 1.9 1.81 1.63 1.23 1.56
0 0 2+ 2+ 0 0 1 2 1 0 0 1 1 0 0 0 0 1 0 0 1,2,3,4 0.95 1.18 1.2 1.04 0 0.95 1.18 1.2 1.04 0 0.85
0 1 2+ 2+ 0 0 1 2 1 0 0 1 1 0 0 0 0 1 0 0 1,2,3,4 0.95 1.18 1.2 0 0 0.95 1.18 1.2 0 0 0.85
0.95 1.18 1.2 0 0 0.95 1.18 1.2 0 0 0.85
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1.7 2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52 1.7
0 0 0 0 0 0 1 2 1 0 0 0 0 2 0 0 0 0 0 0 1,5 1.26 1.3 1.36 1.18 0.9 1.26 1.3 1.36 1.18 0.9 1.26
1.4 1.6 1.65 1.34 1.08 1.4 1.6 1.65 1.34 1.08 1.4
0 0 0 0 0 0 1 2 1 0 0 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.81 1.63 1.52 1.56 1.76 1.65 1.63 1.36 1.4
0 0 0 0 0 0 1 2 1 0 0 0 0 0 0 0 0 0 0 0 1,2 1.56 1.76 1.81 1.63 1.52 1.56 1.76 1.65 1.63 1.36 1.4
1.56 1.76 1.81 1.63 1.52 1.56 1.76 1.65 1.63 1.36 1.4
0 0 1+ 1+ 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 1,2,5 1.56 1.76 1.65 1.34 1.08 1.4 1.6 1.65 1.48 0.9 1.11
0 0 1+ 1+ 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 1,2,5 1.56 1.76 1.65 1.34 1.08 1.4 1.6 1.65 1.48 0.9 1.11
1.56 1.76 1.65 1.34 1.08 1.4 1.6 1.65 1.48 0.9 1.11
3 6 12 18 1.
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3
1.6 1.65 1.34 0.9 1.26 1.46 1.52 1.18 0.78
1.9 1.95 1.78 1.36 1.7 1.9 1.95 1.78 1.36
1.76 1.81 1.63 1.36 1.4 1.6 1.65 1.34 1.08 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 1 0 0 0 0 1 1 1 1 0 0 1
1.76 1.65 1.48 1.08 1.4 1.6 1.52 1.18 0.9
1.76 1.65 1.48 1.08 1.4 1.6 1.52 1.18 0.9
1.76 1.65 1.48 1.08 1.4 1.6 1.52 1.18 0.9 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 1 0 0 0 0 1 1 1 1 1 1 1
1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52
1.76 1.81 1.63 1.36 1.56 1.6 1.65 1.34 0.9
1.6 1.81 1.48 1.23 1.56 1.76 1.65 1.48 1.23 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 1 0 0 0 0 1 1 1 1 0 0 1
1.46 1.52 1.34 1.08 1.11 1.3 1.36 1.04 0.78
1.46 1.52 1.34 1.08 1.11 1.3 1.36 1.04 0.78
1.46 1.52 1.34 1.08 1.11 1.3 1.36 1.04 0.6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 1
1.9 1.95 1.63 1.52 1.7 1.9 1.81 1.63 1.36
1.6 1.65 1.48 1.23 1.4 1.46 1.52 1.34 1.08
1.6 1.65 1.48 1.23 1.56 1.46 1.52 1.34 1.08 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0
1.76 1.65 1.48 1.23 1.4 1.46 1.52 1.34 0.9
2.06 2.11 1.93 1.52 1.85 2.06 2.11 1.93 1.52
1.76 1.81 1.63 1.23 1.56 1.6 1.65 1.48 1.08 0 0 0 0 0 1 0 0 1 0 0 0 1 0 1 1 0 0 0 0 0 1 0 0 0 0 1 1 1 1 1 0 1
1.6 1.52 1.48 1.08 1.56 1.6 1.52 1.34 1.08
1.9 1.81 1.63 1.36 1.7 1.9 1.81 1.63 1.36
1.6 1.52 1.34 1.08 1.56 1.76 1.65 1.18 1.08 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 1
2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52
1.3 1.36 1.18 0.9 1.11 1.3 1.2 1.04 0
1.46 1.52 1.18 0.9 1.4 1.3 1.36 1.18 0.78 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1 1 1 2 2 2 2 2 2 2
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
1.46 1.52 1.34 1.08 1.11 1.18 1.2 1.04 0.78
1.46 1.52 1.34 1.08 1.11 1.18 1.2 1.04 0.78
1.46 1.52 1.34 1.08 1.11 1.18 1.2 1.04 0.78 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 2 2 2 2 2 1 2
1.6 1.52 1.34 0.9 1.4 1.6 1.52 1.34 0.9
2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52
1.76 1.81 1.48 0.9 1.4 1.6 1.52 1.18 0.9 0 0 0 0 0 1 0 0 1 0 0 1 1 0 1 1 0 0 0 0 0 1 1 1 1 1 2 2 2 2 2 2 2
2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.63 1.36
1.18 1.08 0 0 0.95 0 0 0 0
1.3 1.36 1.18 0.9 1.11 1.3 1.2 0.9 0.78 2 2 2 2 2 3 1 1 3 1 1 2 2 2 2 3 3 1 1 1 1 3 3 3 2 3 3 3 3 3 3 3 3
1.46 1.52 1.34 0.9 1.11 1.3 1.36 1.04 0.78
1.46 1.52 1.34 0.9 1.11 1.3 1.36 1.04 0.78
1.46 1.52 1.34 0.9 1.11 1.3 1.36 1.04 0.78 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2
1.6 1.81 1.48 1.36 1.4 1.6 1.81 1.48 1.23
2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66
1.76 1.81 1.63 1.36 1.56 1.76 1.81 1.48 1.23 0 0 0 0 0 1 0 0 1 0 0 1 1 0 0 0 0 0 0 0 0 1 1 1 0 1 1 1 1 1 1 1 1
1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52
1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52
1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52
1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52
1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.04 0.9
1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.04 0.9
1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.04 0.9 0 0 0 0 0 1 0 1 1 1 0 1 1 1 1 1 1 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1
1.6 1.65 1.48 1.23 1.56 1.6 1.65 1.34 1.08
2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66
1.76 1.81 1.48 1.08 1.56 1.76 1.81 1.48 1.08 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 1 1
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
CS (Night)
Visual symptoms scaleWithout glare With glare General functioning scale Psychosocial impact scale
Quality of Life Assessment
1.76 1.65 1.48 1.23 1.4 1.46 1.65 1.48 1.08
1.76 1.65 1.48 1.23 1.4 1.46 1.65 1.48 1.08
1.76 1.65 1.48 1.23 1.4 1.46 1.65 1.48 1.08 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 1 1
2.06 2.11 1.93 1.52 1.85 2.06 2.11 1.93 1.52
1.76 1.65 1.48 1.23 1.4 1.46 1.52 1.34 0.9
1.76 1.81 1.63 1.23 1.56 1.6 1.65 1.48 1.08 0 0 0 0 0 1 0 0 1 0 0 0 1 0 1 1 0 0 0 0 0 1 0 0 0 0 1 1 1 1 1 0 1
1.6 1.52 1.48 1.08 1.56 1.6 1.52 1.34 1.08
1.9 1.81 1.63 1.36 1.7 1.9 1.81 1.63 1.36
1.6 1.52 1.34 1.08 1.56 1.76 1.65 1.18 1.08 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 1
1.3 1.36 1.18 0.9 1.11 1.3 1.2 1.04 0
2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52
1.46 1.52 1.18 0.9 1.4 1.3 1.36 1.18 0.78 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1 1 1 2 2 2 2 2 2 2
1.46 1.52 1.34 0.9 1.11 1.3 1.36 1.04 0.78
1.46 1.52 1.34 0.9 1.11 1.3 1.36 1.04 0.78
1.46 1.52 1.34 0.9 1.11 1.3 1.36 1.04 0.78 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2
1.46 1.52 1.34 1.08 1.11 1.18 1.2 1.04 0.78
1.46 1.52 1.34 1.08 1.11 1.18 1.2 1.04 0.78
1.46 1.52 1.34 1.08 1.11 1.18 1.2 1.04 0.78 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 1 1 2 2 2 2 2 1 2
2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52
1.6 1.52 1.34 0.9 1.4 1.6 1.52 1.34 0.9
1.76 1.81 1.48 0.9 1.4 1.6 1.52 1.18 0.9 0 0 0 0 0 1 0 0 1 0 0 1 1 0 1 1 0 0 0 0 0 1 1 1 1 1 2 2 2 2 2 2 2
1.18 1.08 0 0 0.95 0 0 0 0
2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.63 1.36
1.3 1.36 1.18 0.9 1.11 1.3 1.2 0.9 0.78 2 2 2 2 2 3 1 1 3 1 1 2 2 2 2 3 3 1 1 1 1 3 3 3 2 3 3 3 3 3 3 3 3
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66
1.6 1.81 1.48 1.36 1.4 1.6 1.81 1.48 1.23
1.76 1.81 1.63 1.36 1.56 1.76 1.81 1.48 1.23 0 0 0 0 0 1 0 0 1 0 0 1 1 0 0 0 0 0 0 0 0 1 1 1 0 1 1 1 1 1 1 1 1
1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52
1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52
1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0.78 0 0 0 0 0
0 0 0 0.78 0 0 0 0 0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
1.46 1.52 1.34 1.08 1.4 1.46 1.52 1.34 1.08
2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66
1.76 1.81 1.63 1.36 1.56 1.6 1.65 1.48 1.08 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66
0 0 0 0 0 0 0 0 0
1.3 1.36 1.18 0.9 1.11 1.3 1.36 1.18 0.9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1.6 1.52 1.34 1.08 1.4 1.6 1.52 1.34 1.08
1.6 1.52 1.34 1.08 1.4 1.6 1.52 1.34 1.08
1.6 1.52 1.34 1.08 1.4 1.6 1.52 1.34 1.08 0 0 0 0 0 1 1 1 1 0 0 1 1 0 1 1 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1
0 0 0 0 0 0 0 0 0
2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66
1.18 1.2 1.04 0.78 0.85 1 1.08 0.9 0.6 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
1.76 1.81 1.63 1.36 1.4 1.6 1.65 1.48 1.23
1.76 1.81 1.63 1.36 1.4 1.6 1.65 1.48 1.23
1.76 1.81 1.63 1.36 1.4 1.6 1.65 1.48 1.23 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 1 1
0 0 0 0 0 0 0 0 0
2.06 2.11 1.78 1.52 1.7 2.06 2.11 1.78 1.52
1.3 1.52 1.18 0.9 0.95 1.18 1.2 0.9 0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
0 0 0 0 0 0 0 0 0
0 0 0 0.78 0 0 0 0 0
0 0 0 0.78 0 0 0 0 0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
1.76 1.81 1.63 1.36 1.56 1.76 1.65 1.34 1.08
1.76 1.81 1.63 1.36 1.56 1.76 1.65 1.34 1.08
1.76 1.81 1.63 1.36 1.56 1.76 1.65 1.34 1.08 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.63 1.36
1.18 1.08 0 0 0.95 0 0 0 0
1.3 1.36 1.18 0.9 1.11 1.3 1.2 0.9 0.78 2 2 2 2 2 3 1 1 3 1 1 2 2 2 2 3 3 1 1 1 1 3 3 3 2 3 3 3 3 3 3 3 3
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 3 3 3 3 3 3 3 3 3 3 3 3
1.46 1.52 1.34 1.08 1.4 1.46 1.52 1.34 1.08
2.06 2.11 1.93 1.66 1.85 2.06 2.11 1.93 1.66
1.76 1.81 1.63 1.36 1.56 1.6 1.65 1.48 1.08 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
2.06 2.11 1.78 1.52 1.7 2.06 2.11 1.78 1.52
1.3 1.52 1.18 0.9 0.95 1.18 1.2 0.9 0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
0 0 0 0 0 0 0 0 0
0 0 0 0.78 0 0 0 0 0
0 0 0 0.78 0 0 0 0 0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52
1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52
1.9 1.95 1.78 1.52 1.7 1.9 1.95 1.78 1.52 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52
1.3 1.36 1.18 0.9 1.11 1.3 1.2 1.04 0
1.46 1.52 1.18 0.9 1.4 1.3 1.36 1.18 0.78 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1 1 1 2 2 2 2 2 2 2
1.76 1.81 1.63 1.36 1.56 1.76 1.65 1.34 1.08
1.76 1.81 1.63 1.36 1.56 1.76 1.65 1.34 1.08
1.76 1.81 1.63 1.36 1.56 1.76 1.65 1.34 1.08 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1.46 1.52 1.34 0.9 1.11 1.3 1.36 1.04 0.78
1.46 1.52 1.34 0.9 1.11 1.3 1.36 1.04 0.78
1.46 1.52 1.34 0.9 1.11 1.3 1.36 1.04 0.78 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2
0 0 0 0 0 0 0 0 0
2.06 2.11 1.78 1.52 1.7 2.06 2.11 1.78 1.52
1.3 1.52 1.18 0.9 0.95 1.18 1.2 0.9 0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
1.76 1.65 1.48 1.23 1.4 1.46 1.52 1.34 0.9
2.06 2.11 1.93 1.52 1.85 2.06 2.11 1.93 1.52
1.76 1.81 1.63 1.23 1.56 1.6 1.65 1.48 1.08 0 0 0 0 0 1 0 0 1 0 0 0 1 0 1 1 0 0 0 0 0 1 0 0 0 0 1 1 1 1 1 0 1
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
2.06 1.95 1.78 1.52 1.7 2.06 1.95 1.78 1.52
1.3 1.36 1.18 0.9 1.11 1.3 1.2 1.04 0
1.46 1.52 1.18 0.9 1.4 1.3 1.36 1.18 0.78 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1 1 1 2 2 2 2 2 2 2
1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.04 0.9
1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.04 0.9
1.6 1.65 1.48 1.23 1.4 1.6 1.65 1.04 0.9 0 0 0 0 0 1 0 1 1 1 0 1 1 1 1 1 1 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1
1.3 1.36 1.18 0.78 1.11 1.3 1.2 1.04 0.6
1.3 1.36 1.18 0.78 1.11 1.3 1.2 1.04 0.6
1.3 1.36 1.18 0.78 1.11 1.3 1.2 1.04 0.6 1 1 1 1 1 2 2 2 2 1 1 1 1 1 2 2 1 0 0 0 0 2 2 1 1 2 2 2 2 2 2 2 2
 
 
 
 
 
  
 
 
 
 
 
